1
|
Gongala S, Garcia JA, Korakavi N, Patil N, Akbari H, Sloan A, Barnholtz-Sloan JS, Sun J, Griffith B, Poisson LM, Booth TC, Jain R, Mohan S, Nasralla MP, Bakas S, Tippareddy C, Puig J, Palmer JD, Shi W, Colen RR, Sotiras A, Ahn SS, Park YW, Davatzikos C, Badve C. Sex-specific Differences in IDH1-Wildtype Glioblastoma patients in the ReSPOND Consortium. AJNR Am J Neuroradiol 2024:ajnr.A8319. [PMID: 38684319 DOI: 10.3174/ajnr.a8319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Accepted: 04/17/2024] [Indexed: 05/02/2024]
Abstract
BACKGROUND Understanding sex-based differences in glioblastoma patients is necessary for accurate personalized treatment planning to improve patient outcomes. PURPOSE To investigate sex-specific differences in molecular, clinical and radiological tumor parameters, as well as survival outcomes in glioblastoma, isocitrate dehydrogenase-1 wildtype (IDH1-WT), grade 4 patients. METHODS Retrospective data of 1832 glioblastoma, IDH1-WT patients with comprehensive information on tumor parameters was acquired from the Radiomics Signatures for Precision Oncology in Glioblastoma (ReSPOND) consortium. Data imputation was performed for missing values. Sex-based differences in tumor parameters, such as, age, molecular parameters, pre-operative KPS score, tumor volumes, epicenter and laterality were assessed through non-parametric tests. Spatial atlases were generated using pre-operative MRI maps to visualize tumor characteristics. Survival time analysis was performed through log-rank tests and Cox proportional hazard analyses. RESULTS GBM was diagnosed at a median age of 64 years in females compared to 61.9 years in males (FDR = 0.003). Males had a higher Karnofsky Performance Score (above 80) as compared to females (60.4% females Vs 69.7% males, FDR = 0.044). Females had lower tumor volumes in enhancing (16.7 cm3 Vs. 20.6 cm3 in males, FDR = 0.001), necrotic core (6.18 cm3 Vs. 7.76 cm3 in males, FDR = 0.001) and edema regions (46.9 cm3 Vs. 59.2 cm3 in males, FDR = 0.0001). Right temporal region was the most common tumor epicenter in the overall population. Right as well as left temporal lobes were more frequently involved in males. There were no significant differences in survival outcomes and mortality ratios. Higher age, unmethylated O6-methylguanine-DNAmethyltransferase (MGMT) promoter and undergoing subtotal resection increased the mortality risk in both males and females. CONCLUSIONS Our study demonstrates significant sex-based differences in clinical and radiological tumor parameters of glioblastoma, IDH1-WT, grade 4 patients. Sex is not an independent prognostic factor for survival outcomes and the tumor parameters influencing patient outcomes are identical for males and females. ABBREVIATIONS IDH1-WT = isocitrate dehydrogenase-1 wildtype; MGMTp = O6-methylguanine-DNA-methyltransferase promoter; KPS = Karnofsky performance score; EOR = extent of resection; WHO = world health organization; FDR = false discovery rate.
Collapse
Affiliation(s)
- Sree Gongala
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Jose A Garcia
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Nisha Korakavi
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Nirav Patil
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Hamed Akbari
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Andrew Sloan
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Jill S Barnholtz-Sloan
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Jessie Sun
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Brent Griffith
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Laila M Poisson
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Thomas C Booth
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Rajan Jain
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Suyash Mohan
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - MacLean P Nasralla
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Spyridon Bakas
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Charit Tippareddy
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Josep Puig
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Joshua D Palmer
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Wenyin Shi
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Rivka R Colen
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Aristeidis Sotiras
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Sung Soo Ahn
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Yae Won Park
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Christos Davatzikos
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| | - Chaitra Badve
- From the Department of Radiology, Case Western Reserve University, Cleveland, OH, USA (S.G., N.K., J.S., C.T., C.B.), Department of Radiology, University Hospitals of Cleveland, Cleveland, OH, USA (S.G., N.K., C.D.), Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA (J.A.G., C.D.), Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (J.A.G., S.M., C.D.), Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (N.P.), University Hospitals Health System, Research and Education Institute (N.P.), Department of Bioengineering, Santa Clara University, Santa Clara, California, USA (H.A.), Neuroscience Service line, Department of Neurosurgery, Piedmont Health, Atlanta, Georgia, USA (A.S.), Department of Cancer Biology, Case Comprehensive Cancer Center, Cleveland, Ohio, USA (A.S.), Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA (J.S.B-S.), Department of Radiology, Henry Ford Health, Detroit, MI, USA (B.G.), Department of Radiology, Wayne State University School of Medicine Henry Ford (L.M.P.), School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK (T.C.B.), Department of Neuroradiology, King's College Hospital NHS Foundation Trust, London, UK (T.C.B.), Departments of Radiology and Neurosurgery, New York University Langone Health, New York, NY, USA (R.J.), Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA (M.P.N), Division of Computational Pathology, Department of Pathology and Laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Radiology and Imaging Sciences, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Department of Neurological Surgery, School of Medicine, Indiana University, Indianapolis, IN, USA (S.B.), Radiology Department CDI, Hospital Clinic of Barcelona, Barcelona, Spain (J.P.), Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA (J.D.P.), Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA (W.S.), Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA (R.R.C.), Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (R.R.C.), Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA (A.S.), Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, Republic of Korea (S.S.A., Y.W.P.,)
| |
Collapse
|
2
|
Malta TM, Sabedot TS, Morosini NS, Datta I, Garofano L, Vallentgoed W, Varn FS, Aldape K, D'Angelo F, Bakas S, Barnholtz-Sloan JS, Gan HK, Hasanain M, Hau AC, Johnson KC, Cazacu S, deCarvalho AC, Khasraw M, Kocakavuk E, Kouwenhoven MC, Migliozzi S, Niclou SP, Niers JM, Ormond DR, Paek SH, Reifenberger G, Sillevis Smitt PA, Smits M, Stead LF, van den Bent MJ, Van Meir EG, Walenkamp A, Weiss T, Weller M, Westerman BA, Ylstra B, Wesseling P, Lasorella A, French PJ, Poisson LM, Verhaak RG, Iavarone A, Noushmehr H. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. Cancer Res 2024; 84:741-756. [PMID: 38117484 PMCID: PMC10911804 DOI: 10.1158/0008-5472.can-23-2093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 09/15/2023] [Accepted: 12/13/2023] [Indexed: 12/21/2023]
Abstract
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histologic progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neoangiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution toward an IDHwt-like phenotype. SIGNIFICANCE Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble treatment-naïve IDHwt glioma.
Collapse
Affiliation(s)
- Tathiane M. Malta
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
| | - Thais S. Sabedot
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan
| | | | - Indrani Datta
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan
| | - Luciano Garofano
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
| | - Wies Vallentgoed
- Neurology Department, The Brain Tumour Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Frederick S. Varn
- The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut
| | | | - Fulvio D'Angelo
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
- Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida
| | - Spyridon Bakas
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | | | - Hui K. Gan
- Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia
| | - Mohammad Hasanain
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
| | | | - Kevin C. Johnson
- Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut
| | - Simona Cazacu
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan
| | - Ana C. deCarvalho
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan
| | | | - Emre Kocakavuk
- Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), National Center for Tumor Diseases (NCT) West, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Mathilde C.M. Kouwenhoven
- Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Simona Migliozzi
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
| | | | - Johanna M. Niers
- Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - D. Ryan Ormond
- University of Colorado School of Medicine, Department of Neurosurgery, Aurora, Colorado
| | - Sun Ha Paek
- Department of Neurosurgery, Cancer Research Institute, Hypoxia Ischemia Disease Institute, Seoul National University, Seoul, Republic of Korea (South)
| | - Guido Reifenberger
- Institute of Neuropathology, Heinrich Heine University, Dusseldorf, Germany
| | - Peter A. Sillevis Smitt
- Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- The Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Marion Smits
- Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands
| | - Lucy F. Stead
- Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
| | - Martin J. van den Bent
- Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- The Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Erwin G. Van Meir
- Department of Neurosurgery and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama
| | | | - Tobias Weiss
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
| | - Michael Weller
- Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
| | - Bart A. Westerman
- Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Bauke Ylstra
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Pieter Wesseling
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- Brain Tumor Center Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands
- Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Anna Lasorella
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
- Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida
| | - Pim J. French
- Neurology Department, The Brain Tumour Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Laila M. Poisson
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan
| | - Roel G.W. Verhaak
- Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut
- Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands
| | - Antonio Iavarone
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida
- Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida
| | - Houtan Noushmehr
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan
| |
Collapse
|
3
|
Datta I, Zahoor I, Ata N, Rashid F, Cerghet M, Rattan R, Poisson LM, Giri S. Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis. bioRxiv 2024:2024.02.07.579252. [PMID: 38370675 PMCID: PMC10871325 DOI: 10.1101/2024.02.07.579252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Introduction Multiple sclerosis (MS) is the most common inflammatory neurodegenerative disease of the central nervous system (CNS) in young adults and results in progressive neurological defects. The relapsing-remitting phenotype (RRMS) is the most common disease course in MS and may progress to the progressive form (PPMS). Objectives There is a gap in knowledge regarding whether the relapsing form can be distinguished from the progressive course or healthy subjects (HS) based on an altered serum metabolite profile. In this study, we performed global untargeted metabolomics with the 2D GCxGC-MS platform to identify altered metabolites between RRMS, PPMS, and HS. Methods We profiled 235 metabolites in the serum of patients with RRMS (n=41), PPMS (n=31), and HS (n=91). A comparison of RRMS and HS patients revealed 22 significantly altered metabolites at p<0.05 (false discovery rate [FDR]=0.3). The PPMS and HS comparisons revealed 28 altered metabolites at p<0.05 (FDR=0.2). Results Pathway analysis using MetaboAnalyst revealed enrichment of four metabolic pathways in both RRMS and PPMS (hypergeometric test p<0.05): 1) galactose metabolism; 2) amino sugar and nucleotide sugar metabolism; 3) phenylalanine, tyrosine, and tryptophan biosynthesis; and 4) aminoacyl-tRNA biosynthesis. The Qiagen IPA enrichment test identified the sulfatase 2 (SULF2) (p=0.0033) and integrin subunit beta 1 binding protein 1 (ITGB1BP1) (p=0.0067) genes as upstream regulators of altered metabolites in the RRMS vs. HS groups. However, in the PPMS vs. HS comparison, valine was enriched in the neurodegeneration of brain cells (p=0.05), and heptadecanoic acid, alpha-ketoisocaproic acid, and glycerol participated in inflammation in the CNS (p=0.03). Conclusion Overall, our study suggested that RRMS and PPMS may contribute metabolic fingerprints in the form of unique altered metabolites for discriminating MS disease from HS, with the potential for constructing a metabolite panel for progressive autoimmune diseases such as MS.
Collapse
Affiliation(s)
- Indrani Datta
- Department of Public Health Sciences, Henry Ford Health, Detroit, MI, 48202, USA
- Department of Neurosurgery, Henry Ford Health, Detroit, MI, 48202, USA
| | - Insha Zahoor
- Department of Neurology, Henry Ford Health, Detroit, MI, 48202, USA
| | - Nasar Ata
- Department of Neurology, Henry Ford Health, Detroit, MI, 48202, USA
| | - Faraz Rashid
- Department of Neurology, Henry Ford Health, Detroit, MI, 48202, USA
| | - Mirela Cerghet
- Department of Neurology, Henry Ford Health, Detroit, MI, 48202, USA
| | - Ramandeep Rattan
- Women’s Health Services, Henry Ford Health, Detroit, MI, 48202, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Health, Detroit, MI, 48202, USA
| | - Shailendra Giri
- Department of Neurology, Henry Ford Health, Detroit, MI, 48202, USA
| |
Collapse
|
4
|
Poisson LM, Kaur N, Felicella MM, Singh J. System-based integrated metabolomics and microRNA analysis identifies potential molecular alterations in human X-linked cerebral adrenoleukodystrophy brain. Hum Mol Genet 2023; 32:3249-3262. [PMID: 37656183 PMCID: PMC10656705 DOI: 10.1093/hmg/ddad144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 08/24/2023] [Indexed: 09/02/2023] Open
Abstract
X-linked adrenoleukodystrophy is a severe demyelinating neurodegenerative disease mainly affecting males. The severe cerebral adrenoleukodystrophy (cALD) phenotype has a poor prognosis and underlying mechanism of onset and progression of neuropathology remains poorly understood. In this study we aim to integrate metabolomic and microRNA (miRNA) datasets to identify variances associated with cALD. Postmortem brain tissue samples from five healthy controls (CTL) and five cALD patients were utilized in this study. White matter from ALD patients was obtained from normal-appearing areas, away from lesions (NLA) and from the periphery of lesions- plaque shadow (PLS). Metabolomics was performed by gas chromatography coupled with time-of-flight mass spectrometry and miRNA expression analysis was performed by next generation sequencing (RNAseq). Principal component analysis revealed that among the three sample groups (CTL, NLA and PLS) there were 19 miRNA, including several novel miRNA, of which 17 were increased with disease severity and 2 were decreased. Untargeted metabolomics revealed 13 metabolites with disease severity-related patterns with 7 increased and 6 decreased with disease severity. Ingenuity pathway analysis of differentially altered metabolites and miRNA comparing CTL with NLA and NLA with PLS, identified several hubs of metabolite and signaling molecules and their upstream regulation by miRNA. The transomic approach to map the crosstalk between miRNA and metabolomics suggests involvement of specific molecular and metabolic pathways in cALD and offers opportunity to understand the complex underlying mechanism of disease severity in cALD.
Collapse
Affiliation(s)
- Laila M Poisson
- Department of Public Health Science, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, Michigan 48202, United States
| | - Navtej Kaur
- Department of Neurology, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, Michigan 48202, United States
| | - Michelle M Felicella
- Department of Pathology, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, Michigan 48202, United States
| | - Jaspreet Singh
- Department of Neurology, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, Michigan 48202, United States
| |
Collapse
|
5
|
Herrgott GA, Snyder JM, She R, Malta TM, Sabedot TS, Lee IY, Pawloski J, Podolsky-Gondim GG, Asmaro KP, Zhang J, Cannella CE, Nelson K, Thomas B, deCarvalho AC, Hasselbach LA, Tundo KM, Newaz R, Transou A, Morosini N, Francisco V, Poisson LM, Chitale D, Mukherjee A, Mosella MS, Robin AM, Walbert T, Rosenblum M, Mikkelsen T, Kalkanis S, Tirapelli DPC, Weisenberger DJ, Carlotti CG, Rock J, Castro AV, Noushmehr H. Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas. Nat Commun 2023; 14:5669. [PMID: 37704607 PMCID: PMC10499807 DOI: 10.1038/s41467-023-41434-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 08/31/2023] [Indexed: 09/15/2023] Open
Abstract
Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.
Collapse
Affiliation(s)
- Grayson A Herrgott
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - James M Snyder
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Ruicong She
- Department of Public Health, Biostatistics, Henry Ford Health, Detroit, MI, USA
| | - Tathiane M Malta
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Thais S Sabedot
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Ian Y Lee
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Jacob Pawloski
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Guilherme G Podolsky-Gondim
- Department of Neurosurgery, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil
| | - Karam P Asmaro
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Jiaqi Zhang
- Department of Public Health, Biostatistics, Henry Ford Health, Detroit, MI, USA
| | - Cara E Cannella
- Department of Public Health, Biostatistics, Henry Ford Health, Detroit, MI, USA
| | - Kevin Nelson
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Bartow Thomas
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Ana C deCarvalho
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Laura A Hasselbach
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Kelly M Tundo
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Rehnuma Newaz
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Andrea Transou
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Natalia Morosini
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Victor Francisco
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Laila M Poisson
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
- Department of Public Health, Biostatistics, Henry Ford Health, Detroit, MI, USA
| | | | - Abir Mukherjee
- Department of Pathology, Henry Ford Health, Detroit, MI, USA
| | - Maritza S Mosella
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Adam M Robin
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Tobias Walbert
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Mark Rosenblum
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Tom Mikkelsen
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Steven Kalkanis
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Daniela P C Tirapelli
- Department of Neurosurgery, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil
| | - Daniel J Weisenberger
- Department of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA
| | - Carlos G Carlotti
- Department of Neurosurgery, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil
| | - Jack Rock
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA
| | - Ana Valeria Castro
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA.
- Department of Physiology, Michigan State University, E. Lansing, MI, USA.
| | - Houtan Noushmehr
- Department of Neurosurgery, Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI, USA.
- Department of Physiology, Michigan State University, E. Lansing, MI, USA.
| |
Collapse
|
6
|
Lee MD, Patel SH, Mohan S, Akbari H, Bakas S, Nasrallah MP, Calabrese E, Rudie J, Villanueva-Meyer J, LaMontagne P, Marcus DS, Colen RR, Balana C, Choi YS, Badve C, Barnholtz-Sloan JS, Sloan AE, Booth TC, Palmer JD, Dicker AP, Flanders AE, Shi W, Griffith B, Poisson LM, Chakravarti A, Mahajan A, Chang S, Orringer D, Davatzikos C, Jain R. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium. Neuroradiology 2023; 65:1343-1352. [PMID: 37468750 PMCID: PMC11058040 DOI: 10.1007/s00234-023-03196-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 07/07/2023] [Indexed: 07/21/2023]
Abstract
PURPOSE While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas. METHODS Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS). RESULTS One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS. CONCLUSION Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
Collapse
Affiliation(s)
- Matthew D Lee
- Department of Radiology, NYU Grossman School of Medicine, New York, NY, USA.
| | - Sohil H Patel
- Department of Radiology, University of Virginia School of Medicine, Charlottesville, VA, USA
| | - Suyash Mohan
- Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Hamed Akbari
- Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Spyridon Bakas
- Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - MacLean P Nasrallah
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Glioblastoma Multiforme Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Evan Calabrese
- Department of Radiology, Division of Neuroradiology, Duke University, Durham, NC, USA
| | - Jeffrey Rudie
- Department of Radiology, University of California San Diego, San Diego, CA, USA
| | - Javier Villanueva-Meyer
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
| | - Pamela LaMontagne
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Daniel S Marcus
- Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
| | - Rivka R Colen
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
- Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Carmen Balana
- Medical Oncology Department, Catalan Institute of Oncology (ICO), Barcelona, Spain
| | - Yoon Seong Choi
- Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, South Korea
| | - Chaitra Badve
- Department of Radiology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA
| | - Jill S Barnholtz-Sloan
- Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA
- Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Andrew E Sloan
- Department of Neurosurgery, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA
- Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH, USA
| | - Thomas C Booth
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
- Department of Neuroradiology, King's College Hospital NHS Foundation Trust, Ruskin WingLondon, UK
| | - Joshua D Palmer
- Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Adam P Dicker
- Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Adam E Flanders
- Department of Radiology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Wenyin Shi
- Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Brent Griffith
- Department of Radiology, Henry Ford Health, Detroit, MI, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Center for Bioinformatics, Henry Ford Health, Detroit, MI, USA
| | - Arnab Chakravarti
- Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Abhishek Mahajan
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
| | - Susan Chang
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
| | - Daniel Orringer
- Department of Neurosurgery, NYU Grossman School of Medicine, New York, NY, USA
- Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA
| | - Christos Davatzikos
- Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA
- Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - Rajan Jain
- Department of Radiology, NYU Grossman School of Medicine, New York, NY, USA
- Department of Neurosurgery, NYU Grossman School of Medicine, New York, NY, USA
| |
Collapse
|
7
|
Zahoor I, Suhail H, Datta I, Ahmed ME, Poisson LM, Waters J, Rashid F, Bin R, Singh J, Cerghet M, Kumar A, Hoda MN, Rattan R, Mangalam AK, Giri S. Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target. Proc Natl Acad Sci U S A 2022; 119:e2123265119. [PMID: 35700359 PMCID: PMC9231486 DOI: 10.1073/pnas.2123265119] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Accepted: 04/06/2022] [Indexed: 02/06/2023] Open
Abstract
Metabolic aberrations impact the pathogenesis of multiple sclerosis (MS) and possibly can provide clues for new treatment strategies. Using untargeted metabolomics, we measured serum metabolites from 35 patients with relapsing-remitting multiple sclerosis (RRMS) and 14 healthy age-matched controls. Of 632 known metabolites detected, 60 were significantly altered in RRMS. Bioinformatics analysis identified an altered metabotype in patients with RRMS, represented by four changed metabolic pathways of glycerophospholipid, citrate cycle, sphingolipid, and pyruvate metabolism. Interestingly, the common upstream metabolic pathway feeding these four pathways is the glycolysis pathway. Real-time bioenergetic analysis of the patient-derived peripheral blood mononuclear cells showed enhanced glycolysis, supporting the altered metabolic state of immune cells. Experimental autoimmune encephalomyelitis mice treated with the glycolytic inhibitor 2-deoxy-D-glucose ameliorated the disease progression and inhibited the disease pathology significantly by promoting the antiinflammatory phenotype of monocytes/macrophage in the central nervous system. Our study provided a proof of principle for how a blood-based metabolomic approach using patient samples could lead to the identification of a therapeutic target for developing potential therapy.
Collapse
Affiliation(s)
- Insha Zahoor
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Hamid Suhail
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Indrani Datta
- Department of Public Health Sciences, Henry Ford Health System, Detroit, MI 48202
| | | | - Laila M. Poisson
- Department of Public Health Sciences, Henry Ford Health System, Detroit, MI 48202
| | - Jeffrey Waters
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Faraz Rashid
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Rui Bin
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Jaspreet Singh
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Mirela Cerghet
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Ashok Kumar
- Department of Anatomy and Cell Biology, School of Medicine, Wayne State University, Detroit, MI 48202
| | - Md Nasrul Hoda
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| | - Ramandeep Rattan
- Women’s Health Services, Henry Ford Health System, Detroit, MI 48202
| | - Ashutosh K. Mangalam
- Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA 5224
| | - Shailendra Giri
- Department of Neurology, Henry Ford Health System, Detroit, MI 48202
| |
Collapse
|
8
|
Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LA, Malta TM, Wade TE, Sabedot TS, Brat DJ, Gould PV, Wöehrer A, Aldape K, Ismail A, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Sivajothi S, Datta I, Barnholtz-Sloan JS, Bakas S, D'Angelo F, Gan HK, Garofano L, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AM, Watts C, Weller M, Weiss T, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RG. Abstract 2168: Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Diffuse glioma is characterized by a poor prognosis and a universal resistance to therapy, though the evolutionary processes behind this resistance remain unclear. The Glioma Longitudinal Analysis (GLASS) Consortium has previously demonstrated that therapy-induced selective pressures shape the genetic evolution of glioma in a stochastic manner. However, single-cell studies have revealed that malignant glioma cells are highly plastic and transition their cell state in response to diverse challenges, including changes in the microenvironment and the administration of standard-of-care therapy. To interrogate the factors driving therapy resistance in diffuse glioma, we collected and analyzed RNA- and/or DNA-sequencing data from temporally separated tumor pairs of over 300 adult patients with IDH-wild-type or IDH-mutant glioma. In a subset of these tumor pairs, we additionally performed multiplex immunofluorescence to capture the spatial relationship between tumor cells and their microenvironment. Recurrent tumors exhibited diverse changes that were attributable to changes in histological features, somatic alterations, and microenvironment interactions. IDH-wild-type tumors overall were more invasive at recurrence and exhibited increased expression of neuronal signaling programs that reflected a possible role for neuronal interactions in promoting glioma progression. In contrast, recurrent IDH-mutant tumors exhibited a significant increase in proliferative expression programs that correlated with discrete genetic changes. Hypermutation and acquired CDKN2A homozygous deletions associated with an increase in proliferating stem-like malignant cells at recurrence in both glioma subtypes, reflecting active tumor expansion. A transition to the mesenchymal phenotype was associated with the presence of a specific myeloid cell state defined by unique ligand-receptor interactions with malignant cells, providing opportunities to target this transition through therapy. Collectively, our results uncover recurrence-associated changes in genetics and the microenvironment that can be targeted to shape disease progression following initial diagnosis.
Citation Format: Frederick S. Varn, Kevin C. Johnson, Jan Martinek, Jason T. Huse, MacLean P. Nasrallah, Pieter Wesseling, Lee A. Cooper, Tathiane M. Malta, Taylor E. Wade, Thais S. Sabedot, Daniel J. Brat, Peter V. Gould, Adelheid Wöehrer, Kenneth Aldape, Azzam Ismail, Floris P. Barthel, Hoon Kim, Emre Kocakavuk, Nazia Ahmed, Kieron White, Santhosh Sivajothi, Indrani Datta, Jill S. Barnholtz-Sloan, Spyridon Bakas, Fulvio D'Angelo, Hui K. Gan, Luciano Garofano, Mustafa Khasraw, Simona Migliozzi, D. Ryan Ormond, Sun Ha Paek, Erwin G. Van Meir, Annemiek M. Walenkamp, Colin Watts, Michael Weller, Tobias Weiss, Karolina Palucka, Lucy F. Stead, Laila M. Poisson, Houtan Noushmehr, Antonio Iavarone, Roel G. Verhaak, The GLASS Consortium. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2168.
Collapse
Affiliation(s)
| | | | - Jan Martinek
- 1The Jackson Laboratory for Genomic Medicine, Farmington, CT
| | - Jason T. Huse
- 2University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Pieter Wesseling
- 4Amsterdam University Medical Centers/VUmc, Amsterdam, Netherlands
| | - Lee A. Cooper
- 5Feinberg School of Medicine, Northwestern University, Chicago, IL
| | | | - Taylor E. Wade
- 1The Jackson Laboratory for Genomic Medicine, Farmington, CT
| | - Thais S. Sabedot
- 7Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI
| | - Daniel J. Brat
- 5Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Peter V. Gould
- 8Hôpital de l’Enfant-Jésus du CHU de Québec - Université Laval, Quebec City, Quebec, Canada
| | | | | | | | | | - Hoon Kim
- 13Sungkyunkwan University, Seoul, Republic of Korea
| | - Emre Kocakavuk
- 1The Jackson Laboratory for Genomic Medicine, Farmington, CT
| | - Nazia Ahmed
- 11University of Leeds, Leeds, United Kingdom
| | - Kieron White
- 14Royal College of Surgeons in Ireland, Dublin, Ireland
| | | | - Indrani Datta
- 7Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI
| | - Jill S. Barnholtz-Sloan
- 15Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, OH
| | | | | | - Hui K. Gan
- 17Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia
| | | | | | | | | | - Sun Ha Paek
- 20Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Erwin G. Van Meir
- 21School of Medicine and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
| | | | - Colin Watts
- 23University of Birmingham, Birmingham, United Kingdom
| | | | - Tobias Weiss
- 24University Hospital Zurich, Zurich, Switzerland
| | | | | | - Laila M. Poisson
- 7Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI
| | - Houtan Noushmehr
- 7Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI
| | | | - Roel G. Verhaak
- 1The Jackson Laboratory for Genomic Medicine, Farmington, CT
| | | |
Collapse
|
9
|
Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 2022; 185:2184-2199.e16. [PMID: 35649412 PMCID: PMC9189056 DOI: 10.1016/j.cell.2022.04.038] [Citation(s) in RCA: 138] [Impact Index Per Article: 69.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 01/22/2022] [Accepted: 04/28/2022] [Indexed: 12/21/2022]
Abstract
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA sequencing data from the temporally separated tumor pairs of 304 adult patients with isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant glioma. Tumors recurred in distinct manners that were dependent on IDH mutation status and attributable to changes in histological feature composition, somatic alterations, and microenvironment interactions. Hypermutation and acquired CDKN2A deletions were associated with an increase in proliferating neoplastic cells at recurrence in both glioma subtypes, reflecting active tumor growth. IDH-wild-type tumors were more invasive at recurrence, and their neoplastic cells exhibited increased expression of neuronal signaling programs that reflected a possible role for neuronal interactions in promoting glioma progression. Mesenchymal transition was associated with the presence of a myeloid cell state defined by specific ligand-receptor interactions with neoplastic cells. Collectively, these recurrence-associated phenotypes represent potential targets to alter disease progression.
Collapse
Affiliation(s)
- Frederick S Varn
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Kevin C Johnson
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Jan Martinek
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Jason T Huse
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - MacLean P Nasrallah
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Pieter Wesseling
- Amsterdam University Medical Centers/VUmc, Amsterdam, the Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Lee A D Cooper
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Tathiane M Malta
- School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo, Brazil, Ribeirao Preto, São Paulo, Brazil
| | - Taylor E Wade
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Thais S Sabedot
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA
| | - Daniel Brat
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Peter V Gould
- service d'anatomopathologie, Hôpital de l'Enfant-Jésus du Centre hospitalier universitaire de Québec, Université Laval, Quebec City, QC, Canada
| | - Adelheid Wöehrer
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria
| | | | - Azzam Ismail
- Department of Cellular and Molecular Pathology, Leeds Teaching Hospital NHS Trust, St James's University Hospital, Leeds, UK
| | | | - Floris P Barthel
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Cancer and Cell Biology Division, the Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Hoon Kim
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Biopharmaceutical Convergence, Department of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeong gi-do, South Korea
| | - Emre Kocakavuk
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany
| | | | - Kieron White
- Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
| | - Indrani Datta
- Department of Public Health Sciences, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA
| | - Hyo-Eun Moon
- Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
| | | | | | - Ga-Hyun Lee
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Luciano Garofano
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA
| | - Kevin J Anderson
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | | | - Jill S Barnholtz-Sloan
- Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, OH, USA; Center for Biomedical Informatics and Information Technology & Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Spyridon Bakas
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Annette T Byrne
- Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
| | - Fulvio D'Angelo
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA
| | - Hui K Gan
- Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia
| | - Mustafa Khasraw
- Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
| | - Simona Migliozzi
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA
| | - D Ryan Ormond
- Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA
| | - Sun Ha Paek
- Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
| | - Erwin G Van Meir
- Department of Neurosurgery, School of Medicine and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Annemiek M E Walenkamp
- Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands
| | - Colin Watts
- Academic Department of Neurosurgery, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - Tobias Weiss
- Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zürich, Switzerland
| | - Michael Weller
- Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zürich, Switzerland
| | - Karolina Palucka
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | | | - Laila M Poisson
- Department of Public Health Sciences, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA
| | - Houtan Noushmehr
- Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA
| | - Antonio Iavarone
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA; Department of Neurology, Columbia University Medical Center, New York, NY, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - Roel G W Verhaak
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Neurosurgery, Amsterdam University Medical Centers/VUmc, Amsterdam, the Netherlands.
| |
Collapse
|
10
|
Udumula MP, Poisson LM, Dutta I, Tiwari N, Kim S, Chinna-Shankar J, Allo G, Sakr S, Hijaz M, Munkarah AR, Giri S, Rattan R. Divergent Metabolic Effects of Metformin Merge to Enhance Eicosapentaenoic Acid Metabolism and Inhibit Ovarian Cancer In Vivo. Cancers (Basel) 2022; 14:cancers14061504. [PMID: 35326656 PMCID: PMC8946838 DOI: 10.3390/cancers14061504] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 03/07/2022] [Accepted: 03/12/2022] [Indexed: 02/01/2023] Open
Abstract
Metformin is being actively repurposed for the treatment of gynecologic malignancies including ovarian cancer. We investigated if metformin induces analogous metabolic changes across ovarian cancer cells. Functional metabolic analysis showed metformin caused an immediate and sustained decrease in oxygen consumption while increasing glycolysis across A2780, C200, and SKOV3ip cell lines. Untargeted metabolomics showed metformin to have differential effects on glycolysis and TCA cycle metabolites, while consistent increased fatty acid oxidation intermediates were observed across the three cell lines. Metabolite set enrichment analysis showed alpha-linolenic/linoleic acid metabolism as being most upregulated. Downstream mediators of the alpha-linolenic/linoleic acid metabolism, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), were abundant in all three cell lines. EPA was more effective in inhibiting SKOV3 and CaOV3 xenografts, which correlated with inhibition of inflammatory markers and indicated a role for EPA-derived specialized pro-resolving mediators such as Resolvin E1. Thus, modulation of the metabolism of omega-3 fatty acids and their anti-inflammatory signaling molecules appears to be one of the common mechanisms of metformin's antitumor activity. The distinct metabolic signature of the tumors may indicate metformin response and aid the preclinical and clinical interpretation of metformin therapy in ovarian and other cancers.
Collapse
Affiliation(s)
- Mary P. Udumula
- Department of Women’s Health Services, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (M.P.U.); (N.T.); (J.C.-S.); (M.H.); (A.R.M.)
| | - Laila M. Poisson
- Center for Bioinformatics, Department of Public Health Services, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (L.M.P.); (I.D.)
| | - Indrani Dutta
- Center for Bioinformatics, Department of Public Health Services, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (L.M.P.); (I.D.)
| | - Nivedita Tiwari
- Department of Women’s Health Services, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (M.P.U.); (N.T.); (J.C.-S.); (M.H.); (A.R.M.)
| | - Seongho Kim
- Biostatistics and Bioinformatics Core, Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA;
| | - Jasdeep Chinna-Shankar
- Department of Women’s Health Services, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (M.P.U.); (N.T.); (J.C.-S.); (M.H.); (A.R.M.)
| | - Ghassan Allo
- Department of Pathology, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA;
| | - Sharif Sakr
- Department of Gynecology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA;
| | - Miriana Hijaz
- Department of Women’s Health Services, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (M.P.U.); (N.T.); (J.C.-S.); (M.H.); (A.R.M.)
| | - Adnan R. Munkarah
- Department of Women’s Health Services, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (M.P.U.); (N.T.); (J.C.-S.); (M.H.); (A.R.M.)
| | - Shailendra Giri
- Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA;
| | - Ramandeep Rattan
- Department of Women’s Health Services, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI 48202, USA; (M.P.U.); (N.T.); (J.C.-S.); (M.H.); (A.R.M.)
- Department of Oncology, Wayne State School of Medicine, Detroit, MI 48201, USA
- Correspondence: ; Tel.: +313-876-7381; Fax: +313-876-3415
| |
Collapse
|
11
|
Herrgott GA, Asmaro KP, Wells M, Sabedot TS, Malta TM, Mosella MS, Nelson K, Scarpace L, Barnholtz-Sloan JS, Sloan AE, Selman WR, deCarvalho AC, Poisson LM, Mukherjee A, Robin AM, Lee IY, Snyder J, Walbert T, Rosenblum M, Mikkelsen T, Bhan A, Craig J, Kalkanis S, Rock J, Noushmehr H, Castro AV. Detection of Tumor-specific DNA Methylation Markers in the Blood of Patients with Pituitary Neuroendocrine Tumors. Neuro Oncol 2022; 24:1126-1139. [PMID: 35212383 PMCID: PMC9248407 DOI: 10.1093/neuonc/noac050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Background DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect methylome alterations in circulating cell-free DNA (cfDNA) has been reported for several central nervous system (CNS) tumors but not across PitNETs. The aim of the study was to use the liquid biopsy (LB) approach to detect PitNET-specific methylation signatures to differentiate these tumors from other sellar diseases. Methods We profiled the cfDNA methylome (EPIC array) of 59 serum and 41 plasma LB specimens from patients with PitNETs and other CNS diseases (sellar tumors and other pituitary non-neoplastic diseases, lower-grade gliomas, and skull-base meningiomas) or nontumor conditions, grouped as non-PitNET. Results Our results indicated that despite quantitative and qualitative differences between serum and plasma cfDNA composition, both sources of LB showed that patients with PitNETs presented a distinct methylome landscape compared to non-PitNETs. In addition, LB methylomes captured epigenetic features reported in PitNET tissue and provided information about cell-type composition. Using LB-derived PitNETs-specific signatures as input to develop machine-learning predictive models, we generated scores that distinguished PitNETs from non-PitNETs conditions, including sellar tumor and non-neoplastic pituitary diseases, with accuracies above ~93% in independent cohort sets. Conclusions Our results underpin the potential application of methylation-based LB profiling as a noninvasive approach to identify clinically relevant epigenetic markers to diagnose and potentially impact the prognostication and management of patients with PitNETs.
Collapse
Affiliation(s)
- Grayson A Herrgott
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Karam P Asmaro
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Michael Wells
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Thais S Sabedot
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Tathiane M Malta
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Maritza S Mosella
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Kevin Nelson
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Lisa Scarpace
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Jill S Barnholtz-Sloan
- Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, 2103 Cornell Rd, Cleveland, Ohio 44106 USA
| | - Andrew E Sloan
- Department of Neurological Surgery, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106 USA (EAS).,Case Comprehensive Cancer Center, 10900 Euclid Ave., Cleveland, OH 44106 USA (EAS)
| | - Warren R Selman
- Department of Neurological Surgery, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106 USA (EAS)
| | - Ana C deCarvalho
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Laila M Poisson
- Department of Biostatistics, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI, 48202 USA
| | - Abir Mukherjee
- Department of Pathology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI, 48202 USA
| | - Adam M Robin
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Ian Y Lee
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - James Snyder
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Tobias Walbert
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Mark Rosenblum
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Tom Mikkelsen
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Arti Bhan
- Department of Endocrinology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI, 48202 USA
| | - John Craig
- Department of Otolaryngology, Co-director of the Skull Base, Pituitary and Endoscopy Center
| | - Steven Kalkanis
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Jack Rock
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA
| | - Houtan Noushmehr
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| | - Ana Valeria Castro
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202 USA.,Department of Neurosurgery, Omics Laboratory, 2799 West Grand Boulevard, Henry Ford Health System, Detroit, MI 48202 USA
| |
Collapse
|
12
|
Brodie S, Lee HK, Jiang W, Cazacu S, Xiang C, Poisson LM, Datta I, Kalkanis S, Ginsberg D, Brodie C. Correction: The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. Oncotarget 2021; 12:2546-2547. [PMID: 34966487 PMCID: PMC8711573 DOI: 10.18632/oncotarget.27383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
[This corrects the article DOI: 10.18632/oncotarget.15991.].
Collapse
Affiliation(s)
- Shlomit Brodie
- Everard and Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Hae Kyung Lee
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Detroit, MI, USA
| | - Wei Jiang
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Detroit, MI, USA
| | - Simona Cazacu
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Detroit, MI, USA
| | - Cunli Xiang
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Detroit, MI, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Center for Bioinformatics, Henry Ford Hospital, Detroit, MI, USA
| | - Indrani Datta
- Department of Public Health Sciences, Center for Bioinformatics, Henry Ford Hospital, Detroit, MI, USA
| | - Steve Kalkanis
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Detroit, MI, USA
| | - Doron Ginsberg
- Everard and Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Chaya Brodie
- Everard and Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.,Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Detroit, MI, USA
| |
Collapse
|
13
|
Mosella MS, Sabedot TS, Silva TC, Malta TM, Dezem FS, Asmaro KP, Wells M, Mukherjee A, Poisson LM, Snyder J, deCarvalho AC, Walbert T, Aho T, Kalkanis S, Elias PC, Antonini SR, Rock J, Noushmehr H, Castro M, Castro AV. DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features. Neuro Oncol 2021; 23:1292-1303. [PMID: 33631002 DOI: 10.1093/neuonc/noab044] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize, and validate methylation signatures that objectively classify PitNET into clinicopathological groups. METHODS Combining in-house and publicly available data, we conducted an analysis of the methylome profile of a comprehensive cohort of 177 tumors (Panpit cohort) and 20 nontumor specimens from the pituitary gland. We also retrieved methylome data from an independent PitNET cohort (N = 86) to validate our findings. RESULTS We identified three methylation clusters associated with adenohypophyseal cell lineages and functional status using an unsupervised approach. Differentially methylated probes (DMP) significantly distinguished the Panpit clusters and accurately assigned the samples of the validation cohort to their corresponding lineage and functional subtypes memberships. The DMPs were annotated in regulatory regions enriched with enhancer elements, associated with pathways and genes involved in pituitary cell identity, function, tumorigenesis, and invasiveness. Some DMPs correlated with genes with prognostic and therapeutic values in other intra- or extracranial tumors. CONCLUSIONS We identified and validated methylation signatures, mainly annotated in enhancer regions that distinguished PitNETs by distinct adenohypophyseal cell lineages and functional status. These signatures provide the groundwork to develop an unbiased approach to classifying PitNETs according to the most recent classification recommended by the 2017 WHO and to explore their biological and clinical relevance in these tumors.
Collapse
Affiliation(s)
- Maritza S Mosella
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA.,Department of Genetics, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Thais S Sabedot
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Tiago C Silva
- Department of Genetics, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Tathiane M Malta
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Felipe Segato Dezem
- Department of Genetics, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Karam P Asmaro
- Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA
| | - Michael Wells
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Abir Mukherjee
- Department of Pathology, Henry Ford Health System, Detroit, Michigan, USA
| | - Laila M Poisson
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA.,Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA
| | - James Snyder
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Ana C deCarvalho
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Tobias Walbert
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| | - Todd Aho
- Department of Radiology, Henry Ford Health System, Detroit, Michigan, USA
| | - Steven Kalkanis
- Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA
| | - Paula C Elias
- Internal Medicine Department, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Sonir R Antonini
- Department of Pediatrics, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Brazil
| | - Jack Rock
- Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA
| | - Houtan Noushmehr
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA.,Department of Genetics, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Margaret Castro
- Internal Medicine Department, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Sao Paulo, Brazil
| | - Ana Valeria Castro
- Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan, USA
| |
Collapse
|
14
|
Datta I, Malta T, Sabedot T, She R, Iavarone A, Noushmehr H, Poisson LM. Abstract 2085: The evolutionary trajectory of epigenomics in adult glioma. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-2085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Glioma is the most common malignant tumor of the central nervous system, often behaving very aggressively. Recently, The Cancer Genome Atlas (TCGA) and others have shown that epigenomic alterations in primary glioma tumors have prognostic and predictive roles, but there is a gap in knowledge of the molecular alterations after glioma treatment. In order to fill this gap, the Glioma Longitudinal AnalySiS (GLASS) Consortium, a multi-national collaboration from 13 institutions, is investigating genome-wide molecular data from primary and recurrent matched pairs. The current data freeze has DNA methylation data for 266 primary-recurrent pairs fromIllumina 450K and EPIC array platforms.
Methods: We hypothesize that there will be evidence of aggressivity in the DNA methylation profiles of recurrent tumors relative to their matched primary, and we explored this through tumor subtyping, patterns of differentially methylated CpGs (DMPs), and epigenomic aging.
Results: The subtype classification in the primary tumors was as follows for IDH wildtype tumors - 43.8%Classical, 47.3% Mesenchymal, 8.7% PA-like, none LGm6-GBM and for IDH mutant tumors 19.1% Codel, 79.4% G-CIMP-high, 1.3% G-CIMP-low. We observed that among IDH wildtype tumors 29.8% changed subtype, 47.1% of which shifted to the more aggressive Mesenchymal-like subtype. In IDH mutant tumors, 26.0% changed at recurrence, of which 57.9% shifted to the aggressive G-CIMP-low subtype. Patterns of DMPs in IDH mutant-code tumors (15 pairs) showed a loss of methylation upon recurrence, with 651 DMPs identified (paired Wilcoxon test, FDR <0.05). In unsupervised clustering, recurrent Codel tumors thus move away from IDH mutant tumors and align more closely to IDH wildtype tumors. We do not see the same increases in hypomethylation upon recurrence among IDHwt tumors, with only 17 DMPs at FDR <0.05 in the classical subtype (24 pairs). It has been shown that biological age estimates of the tumor using DNA methylation can predict aggressivity of certain tumor types. We examined epigenetic aging changes between primary and recurrent tumors, relative to the patients chronological age, with Horvath (tissue-based) and epiTOC (mitotic-based) DNA methylation clocks. Both clocks showed shifts in age acceleration, that is increased biological age in relation to chronological age. For the Horvath clock, we found increased age acceleration in Classical-like tumors (primary=39.5±8.9, recurrent 41.7± 19.7) and Codel tumors (primary= 57.0±22.3, recurrent= 64.2±31.8).
Conclusions: Collectively, we observed glioma tumor epigenetic changes from the primary to recurrent state and these differences tend to reflect a shift to a more aggressive phenotype. Future work will explore the relationship of these findings with clinical treatments received between primary and recurrent states.
Citation Format: Indrani Datta, Tathi Malta, Thais Sabedot, Ruicong She, The GLASS Consortium, Antonio Iavarone, Houtan Noushmehr, Laila M. Poisson. The evolutionary trajectory of epigenomics in adult glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2085.
Collapse
|
15
|
Malta TM, Datta I, Sabedot T, She R, Castro A, Iavarone A, Poisson LM, Noushmehr H. Abstract 2717: Glioma immune microenvironment change during tumor recurrence. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-2717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Gliomas are the most common malignant brain tumor, have a very aggressive behavior, and invariably relapse and progress. Despite the recent advances, only a few drugs are approved and they present limited success. Currently, there are numerous clinical trials evaluating the efficacy of immunotherapy for gliomas, which are not completed yet. Deciphering the composition of the tumor microenvironment (TME) can have an important and immediate impact on therapeutic interventions and on the development of prognostic and predictive biomarkers for gliomas immunotherapy. To investigate the molecular dynamics over time and in response to therapeutic pressures, the Glioma Longitudinal AnalySiS (GLASS) Consortium, a multinational collaboration, is investigating epigenome-wide molecular data from primary and recurrent matched pairs.
Objective: Our aim is to evaluate glioma TME using the deconvolution method methylCIBERSORT applied to DNA methylation data from GLASS.
Methods: We generated and validated a customized reference signature defining 10 cell types to predict the relative proportions of immune cell type in the TME of 370 glioma specimens, including 132 longitudinal pairs (initial and recurrent tumors) in association with clinical features (recurrence, survival etc).
Results: We found that the TME differs across gliomas of different subtypes. In general, IDHmut subtypes (Codel, GCIMP-high, and GCIMP-low) presented less immune infiltration than IDHwt (Classic-like, Mesenchymal-like, and PA-like). The most abundant estimated infiltrated cell types in IDHmut and IDHwt gliomas were TCD4 cells and macrophages, respectively. Post-treatment (chemo+radiotherapy), we found a decrease of TCD4 and an increase of TCD8 cells in recurrent Codel and G-CIMP-high subtypes; and an increase of macrophages in classic recurrent tumors. High frequency of macrophages and TCD8 cells were associated with poorer overall survival in the IDHwt patients (log-rank p=0.040, hazard ratio (HR) = 1.38; log-rank p=0.046, HR = 2.37, respectively).
Conclusions: Using a DNA methylation-based deconvolution approach, we have described the TME of longitudinal gliomas. We found a TME diversity across glioma molecular subtypes and an association with IDH mutation and overall survival. Our findings indicate that the epigenomic deconvolution of TME has a potential therapeutic and prognostic implication to guide the management of patients with gliomas.
Citation Format: Tathiane Maistro Malta, Indrani Datta, Thais Sabedot, Ruicong She, AnaValeria Castro, GLASS Consortium GLASS Consortium, Antonio Iavarone, Laila M. Poisson, Houtan Noushmehr. Glioma immune microenvironment change during tumor recurrence [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2717.
Collapse
|
16
|
Wang DD, O'Neill WW, Zervos MJ, McKinnon JE, Allard D, Alangaden GJ, Schultz LR, Poisson LM, Chu BS, Kalkanis SN, Suleyman G. Association Between Implementation of a Universal Face Mask Policy for Healthcare Workers in a Health Care System and SARS-CoV-2 Positivity Testing Rate in Healthcare Workers. J Occup Environ Med 2021; 63:476-481. [PMID: 33596025 PMCID: PMC8168668 DOI: 10.1097/jom.0000000000002174] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE Examine the effect of a universal facemask policy for healthcare workers (HCW) and incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity. METHODS Daily number of symptomatic HCW tested, SARS-CoV-2 positivity rates, and HCW job-descriptions were collected pre and post Universal HCW facemask policy (March 26, 2020). Multiple change point regression was used to model positive-test-rate data. SARS-CoV-2 testing and positivity rates were compared for pre-intervention, transition, post-intervention, and follow-up periods. RESULTS Between March 12 and August 10, 2020, 19.2% of HCW were symptomatic for COVID-19 and underwent SARS-CoV-2 testing. A single change point was identified ∼March 28-30 (95% probability). Before the change point, the odds of a tested HCW having a positive result doubled every 4.5 to 7.5 days. Post-change-point, the odds of a tested HCW having a positive result halved every 10.5 to 13.5 days. CONCLUSIONS Universal facemasks were associated with reducing HCW's risk of acquiring COVID-19.
Collapse
Affiliation(s)
- Dee Dee Wang
- Division of Cardiovascular Disease, Center for Structural Heart (Dr Wang, Dr O'Neill); Infectious Disease (Dr Zervos, Dr McKinnon, Dr Alangaden, Dr Suleyman); Family Medicine (Dr Allard); Public Health Sciences (Dr Schultz, Dr Poisson); Office of Clinical Quality and Safety, Henry Ford Health System (Dr Chu); and Department of Neurosurgery (Dr Kalkanis), Henry Ford Hospital, Detroit, Michigan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Datta I, Noushmehr H, Brodie C, Poisson LM. Expression and regulatory roles of lncRNAs in G-CIMP-low vs G-CIMP-high Glioma: an in-silico analysis. J Transl Med 2021; 19:182. [PMID: 33926464 PMCID: PMC8086286 DOI: 10.1186/s12967-021-02844-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 04/18/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Clinically relevant glioma subtypes, such as the glioma-CpG island methylator phenotype (G-CIMP), have been defined by epigenetics. In this study, the role of long non-coding RNAs in association with the poor-prognosis G-CMIP-low phenotype and the good-prognosis G-CMIP-high phenotype was investigated. Functional associations of lncRNAs with mRNAs and miRNAs were examined to hypothesize influencing factors of the aggressive phenotype. METHODS RNA-seq data on 250 samples from TCGA's Pan-Glioma study, quantified for lncRNA and mRNAs (GENCODE v28), were analyzed for differential expression between G-CIMP-low and G-CIMP-high phenotypes. Functional interpretation of the differential lncRNAs was performed by Ingenuity Pathway Analysis. Spearman rank order correlation estimates between lncRNA, miRNA, and mRNA nominated differential lncRNA with a likely miRNA sponge function. RESULTS We identified 4371 differentially expressed features (mRNA = 3705; lncRNA = 666; FDR ≤ 5%). From these, the protein-coding gene TP53 was identified as an upstream regulator of differential lncRNAs PANDAR and PVT1 (p = 0.0237) and enrichment was detected in the "development of carcinoma" (p = 0.0176). Two lncRNAs (HCG11, PART1) were positively correlated with 342 mRNAs, and their correlation estimates diminish after adjusting for either of the target miRNAs: hsa-miR-490-3p, hsa-miR-129-5p. This suggests a likely sponge function for HCG11 and PART1. CONCLUSIONS These findings identify differential lncRNAs with oncogenic features that are associated with G-CIMP phenotypes. Further investigation with controlled experiments is needed to confirm the molecular relationships.
Collapse
Affiliation(s)
- Indrani Datta
- Department of Public Health Sciences, Center for Bioinformatics, Henry Ford Health System, 1 Ford Place, 3C, Detroit, MI, 48202, USA
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, USA
| | - Houtan Noushmehr
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, USA
| | - Chaya Brodie
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Center for Bioinformatics, Henry Ford Health System, 1 Ford Place, 3C, Detroit, MI, 48202, USA.
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, USA.
| |
Collapse
|
18
|
Davatzikos C, Barnholtz-Sloan JS, Bakas S, Colen R, Mahajan A, Quintero CB, Capellades Font J, Puig J, Jain R, Sloan AE, Badve C, Marcus DS, Seong Choi Y, Lee SK, Chang JH, Poisson LM, Griffith B, Dicker AP, Flanders AE, Booth TC, Rathore S, Akbari H, Sako C, Bilello M, Shukla G, Fathi Kazerooni A, Brem S, Lustig R, Mohan S, Bagley S, Nasrallah M, O'Rourke DM. AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium. Neuro Oncol 2021; 22:886-888. [PMID: 32152622 DOI: 10.1093/neuonc/noaa045] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Affiliation(s)
- Christos Davatzikos
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Jill S Barnholtz-Sloan
- Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA
| | - Spyridon Bakas
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Rivka Colen
- Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | | | | | | | - Josep Puig
- Department of Radiology, University of Manitoba Winnipeg, Manitoba, Canada
| | - Rajan Jain
- Department of Radiology, New York University
| | - Andrew E Sloan
- Department of Neurosurgery, Case Western Reserve University, Cleveland, Ohio, USA
| | - Chaitra Badve
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio, USA
| | - Daniel S Marcus
- Department of Radiology, Washington University, St. Louis, Missouri, USA
| | - Yoon Seong Choi
- Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, South Korea.,Department of Diagnostic Radiology, Singapore General Hospital, Singapore
| | - Seung-Koo Lee
- Department of Radiology and Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, South Korea
| | - Jong Hee Chang
- Department of Neurosurgery, Yonsei University College, Seoul, Korea
| | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA
| | - Brent Griffith
- Department of Radiology, Henry Ford Health System, Detroit, Michigan, USA
| | - Adam P Dicker
- Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Adam E Flanders
- Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Thomas C Booth
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, England, UK
| | - Saima Rathore
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Hamed Akbari
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Chiharu Sako
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Michel Bilello
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Gaurav Shukla
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Anahita Fathi Kazerooni
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.,Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Steven Brem
- Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Robert Lustig
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Suyash Mohan
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Stephen Bagley
- Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - MacLean Nasrallah
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Donald M O'Rourke
- Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
19
|
Bakas S, Ormond DR, Alfaro-Munoz KD, Smits M, Cooper LAD, Verhaak R, Poisson LM. iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium. Neuro Oncol 2021; 22:1545-1546. [PMID: 32644158 DOI: 10.1093/neuonc/noaa160] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- Spyridon Bakas
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - David Ryan Ormond
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Kristin D Alfaro-Munoz
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Marion Smits
- Department of Radiology and Nuclear Medicine, Erasmus MC‒University Medical Center Rotterdam, Rotterdam, Netherlands
| | - Lee Alex Donald Cooper
- Department of Pathology, Feinberg School of Medicine, Northwestern Medicine, Northwestern University, Chicago, Illinois, USA
| | - Roel Verhaak
- The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA
| | - Laila M Poisson
- Henry Ford Cancer Institute, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan, USA
| |
Collapse
|
20
|
Cassidy-Bushrow AE, Baseer M, Kippen K, Levin AM, Li J, Loveless I, Poisson LM, Schultz L, Wegienka G, Zhou Y, Johnson CC. Social distancing during the COVID-19 pandemic: quantifying the practice in Michigan - a "hotspot state" early in the pandemic - using a volunteer-based online survey. BMC Public Health 2021; 21:245. [PMID: 33514350 PMCID: PMC7844797 DOI: 10.1186/s12889-021-10287-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 01/20/2021] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Public Health policies related to social distancing efforts during the COVID-19 pandemic helped slow the infection rate. However, individual-level factors associated with social distancing are largely unknown. We sought to examine social distancing during the COVID-19 pandemic in Michigan, an infection "hotspot" state in the United States early in the pandemic. METHODS Two surveys were distributed to Michigan residents via email lists and social media following COVID-19 related state mandates in March; 45,691 adults responded to the first survey and 8512 to the second. Staying home ≥ 3 out of 5 previous days defined having more social distancing. Logistic regression models were used to examine potential factors associated with more social distancing. RESULTS Most respondents were women (86% in Survey 1, 87% in Survey 2). In Survey 1, 63% reported more social distancing, increasing to 78% in Survey 2. Female sex and having someone (or self) sick in the home were consistently associated with higher social distancing, while increasing age was positively associated in Survey 1 but negatively associated in Survey 2. Most respondents felt social distancing policies were important (88% in Survey 1; 91% in Survey 2). CONCLUSIONS Michiganders responding to the surveys were both practicing and supportive of social distancing. State-level executive orders positively impacted behaviors early in the COVID-19 pandemic in Michigan. Additional supports are needed to help vulnerable populations practice social distancing, including older individuals.
Collapse
Affiliation(s)
- Andrea E Cassidy-Bushrow
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA.
| | - Mohammed Baseer
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Karen Kippen
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Albert M Levin
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Jia Li
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Ian Loveless
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Lonni Schultz
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Ganesa Wegienka
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Yueren Zhou
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| | - Christine Cole Johnson
- Department of Public Health Sciences, Henry Ford Hospital, 1 Ford Place, 5C, Detroit, MI, 48202, USA
| |
Collapse
|
21
|
Sabedot T, Wells M, Datta I, Malta T, Castro AV, Poisson LM, Verhaak R, Iavarone A, Noushmehr H. EPCO-29. EPIGENOMICS OF THE GLIOMA LONGITUDINAL ANALYSIS (GLASS) CONSORTIUM. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Adult diffuse gliomas are central nervous system (CNS) tumors that arise from the malignant transformation of glial cells. Nearly all gliomas will recur despite standard treatment however, current histopathological grading fails to predict which of them will relapse and/or progress. The Glioma Longitudinal AnalySiS (GLASS) consortium is a large-scale collaboration that aims to investigate the molecular profiling of matched primary and recurrent glioma samples from multiple institutions in order to better understand the dynamic evolution of these tumors. At this time, the cohort comprises 946 samples across 11 institutions and among those, 864 have DNA methylation data available. The current molecular classification based on 7 subtypes published by TCGA in 2016 was applied to the dataset. Among the IDH wildtype tumors, 33% (16/49) of the patients showed a change of subtype upon recurrence, whereas most of them (9/16) were Classic-like at the primary stage but changed to either Mesenchymal-like or PA-like at the recurrent level. Among the IDH mutant tumors, 15% (22/142) showed a change of subtype at recurrent stage, in which 16 out of 22 progressed from G-CIMP-high to G-CIMP-low. Although some tumors progressed to a different subtype upon recurrence, an unsupervised analysis showed that the samples tend to cluster by patient instead of by subtype. By estimating the copy number alterations of these tumors using DNA methylation, the overall copy number profile of the recurrent samples remains similar to their primary counterpart. From this initial analysis using epigenomic data, we were able to characterize some aspects of glioma evolution and how the DNA methylation is associated with the progression of these tumors to different subtypes. These findings corroborate the importance of epigenetics in gliomas and can potentially lead to the identification of new biomarkers that can reflect tumor burden and predict its development.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Roel Verhaak
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | | | | | | |
Collapse
|
22
|
Horta E, Zhou Y, Poisson LM, Griffith B, Stone M, Snyder J, Walbert T. NCOG-18. IS THE RANO CRITERIA FOR LOW-GRADE GLIOMA RELIABLE IN THE CLINICAL SETTING? – A RELIABILITY STUDY. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
INTRODUCTION
Magnetic resonance imaging (MRI) is a fundamental component of longitudinal neuro-oncology evaluation and decision-making. The Response Assessment in Neuro-Oncology criteria for low-grade gliomas (RANOLGG) was designed as an outcome measure for clinical trials. Thus, this project intends to study the reliability of RANOLGG in the clinic setting.
METHODS
21 pairs of brain MRIs, that averaged three years apart, were selected from 21 patients with tissue diagnosis of WHO grade 2 gliomas. Two neuro-oncologists and two neuro-radiologists reviewed and independently scored the MRI pairs according to RANOLGG categories of progressive disease, stable disease, minor response, partial response, and complete response. Kappa-Fleiss (KF) was used to evaluate agreement among reviewers.
RESULTS
Reviewers awarded identical scores in only 33% of MRI pairs and there was a complete disagreement in one MRI pair. Overall reliability of the criteria in the clinical setting is moderate (KF = 0.44). Agreement between neuroradiologists (KF = 0.51) and between neuro-oncologists (KF = 0.48) were similar. Interpretation of post-contrast T1-weighted images had a better agreement (KF = 0.31) than T2/FLAIR-weighted images which had a poor agreement (KF = -0.02). Classification of progression versus non-progression had only a moderate agreement (KF= 0.49). History of radiation therapy or chemotherapy did not influence the criteria reliability (fisher exact text, p = 0.58, p =0.27, respectively).
CONCLUSION
RANOLGG reliability in the clinical setting is moderate, therefore it should be used cautiously for clinical decision-making. Other tools that can support the neuro-oncologist in the follow-up of patients with low-grade glioma are additional MRI sequences other than T2/FLAIR and contrast – weighted images, computer-aided diagnosis such as volumetrics, spectroscopy, positron emission tomography, and multidisciplinary tumor boards. Likewise, when image criteria for low-grade gliomas are designed, T2/FLAIR should be used guardedly, due to low interpretation agreement.
Collapse
|
23
|
Wang J, Nassiri F, Au K, Drummond K, Jenkinson M, Santarius T, Barnholtz-Sloan JS, Jungk C, DiMeco F, Galanis E, Saladino A, Zhou Y, Suppiah S, Badhiwala J, Aldape K, Poisson LM, Zadeh G. NCOG-55. HARMONIZING LANGUAGE TO MAXIMIZE IMPACT: AN UPDATE ON COMMON DATA ELEMENTS FOR MENINGIOMA AND REVIEW OF CLINICAL TRIALS IN MENINGIOMA. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
With increasing studies reporting on the molecular profiling of meningiomas, there is a need to harmonize language used to capture clinical data across centers to ensure that molecular alterations are appropriately linked to clinical variables of interest. Here the International Consortium on Meningiomas presents a final set of core and supplemental meningioma-specific Common Data Elements (CDEs) to facilitate comparative and pooled analyses.
METHODS
The generation of CDEs followed the four-phase process similar to other National Institute of Neurological Disorders and Stroke (NINDS) CDE projects: development/discovery based on data from published and ongoing meningioma trials, internal validation, external validation including presentation of our data form at the Society for Neuro-Oncology previously, and distribution.
RESULTS
We developed a set of CDEs organized into patient- and tumor-level modules. In total, the Consortium identified 16 core CDEs (9 patient-level and 7-tumour-level) e.g. age at index surgery, diagnosis of neurofibromatosis, prior chemotherapy or radiation, tumor location, extent of resection, recurrence, etc. An additional 15 supplemental CDEs were defined and described (8 patient-level and 7 tumour-level) e.g. race, cause of death, multiple tumors, tumor size, Simpson grade, second intervention, etc. These CDES are now made publicly available for dissemination and adoption. We also present a narrative review and analysis of recent and ongoing meningioma trials.
CONCLUSIONS
These CDEs provide a framework for discussion in the neuro-oncology community that will facilitating data sharing for collaborative research projects and aid in developing a common language for comparative and pooled analyses. The CDEs are intended to be dynamic parameters that evolve with time and The Consortium welcomes international feedback for further refinement and implementation of these CDEs.
Collapse
Affiliation(s)
- Justin Wang
- The University of Toronto, Toronto, ON, Canada
| | | | - Karolyn Au
- University of Alberta, Edmonton, AB, Canada
| | | | | | | | | | | | | | | | | | - Yueren Zhou
- Henry Ford Health Institute, Ann Arbor, MI, USA
| | | | | | - Kenneth Aldape
- National Cancer Institute, National Institute of Health, Bethesda, MD, USA
| | | | - Gelareh Zadeh
- Princess Margaret Cancer Center, Toronto, ON, Canada
| |
Collapse
|
24
|
Bier A, Hong X, Cazacu S, Goldstein H, Rand D, Xiang C, Jiang W, Ben-Asher HW, Attia M, Brodie A, She R, Poisson LM, Brodie C. miR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles. Cell Death Dis 2020; 11:899. [PMID: 33093452 PMCID: PMC7581800 DOI: 10.1038/s41419-020-03088-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Revised: 08/13/2020] [Accepted: 08/24/2020] [Indexed: 12/13/2022]
Abstract
Glioblastoma (GBM) is a highly aggressive tumor with poor prognosis. A small subpopulation of glioma stem cells (GSCs) has been implicated in radiation resistance and tumor recurrence. In this study we analyzed the expression of miRNAs associated with the functions of GSCs using miRNA microarray analysis of these cells compared with human neural stem cells. These analyses identified gene clusters associated with glioma cell invasiveness, axonal guidance, and TGF-β signaling. miR-504 was significantly downregulated in GSCs compared with NSCs, its expression was lower in GBM compared with normal brain specimens and further decreased in the mesenchymal glioma subtype. Overexpression of miR-504 in GSCs inhibited their self-renewal, migration and the expression of mesenchymal markers. The inhibitory effect of miR-504 was mediated by targeting Grb10 expression which acts as an oncogene in GSCs and GBM. Overexpression of exogenous miR-504 resulted also in its delivery to cocultured microglia by GSC-secreted extracellular vesicles (EVs) and in the abrogation of the GSC-induced polarization of microglia to M2 subtype. Finally, miR-504 overexpression prolonged the survival of mice harboring GSC-derived xenografts and decreased tumor growth. In summary, we identified miRNAs and potential target networks that play a role in the stemness and mesenchymal transition of GSCs and the miR-504/Grb10 pathway as an important regulator of this process. Overexpression of miR-504 exerted antitumor effects in GSCs as well as bystander effects on the polarization of microglia via delivery by EVs.
Collapse
Affiliation(s)
- Ariel Bier
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Xin Hong
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
| | - Simona Cazacu
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
| | - Hodaya Goldstein
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Daniel Rand
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Cunli Xiang
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
| | - Wei Jiang
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
| | - Hiba Waldman Ben-Asher
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Moshe Attia
- Department of Neurosurgery, Sheba Medical Center, Henry Ford Hospital, Detroit, MI, USA
| | - Aharon Brodie
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
| | - Ruicong She
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA
| | - Chaya Brodie
- The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
- Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.
| |
Collapse
|
25
|
Chang SS, Hwang C, Elshaikh MA, Tang A, Neslund-Dudas CM, Levin AM, Poisson LM, Rybicki BA. Abstract S09-02: Outcomes by race for cancer patients hospitalized with SARS-CoV-2 infection. Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.covid-19-s09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Disparities in COVID-19 outcomes have been widely reported, with disproportionate negative impacts on the African American (AA) population. The purpose of this study was to evaluate the impact of race on COVID-19 outcomes for cancer patients hospitalized in a large Michigan health care system.
Methods: A cohort of hospitalized, laboratory-confirmed SARS-CoV-2 positive patients was identified through the Henry Ford Health System Institutional COVID prospective patient registry between March 1st–May 2020. Those with a diagnosis of cancer were identified using our institutional tumor registry and electronic health record (EHR). Patient self-reported race/ethnicity data were extracted from the system’s centralized EHR, as were other demographic and clinical covariates. Racial differences in cumulative incidence of mortality and hospital discharge were tested. To further evaluate the effect of race on the mortality, Fine-Gray competing-risks model was performed with discharge alive as a competing event. A P<0.05 was considered statistically significant.
Results: Out of the 204 COVID+ cancer patients hospitalized in our health care system, 69.6% were AA (N=142). AA patients were slightly younger than non-AA patients (70.35 v. 74.58, p=0.023). No difference in mean BMI was detected (30.33 AA v. 29.87 non-AA, p = 0.68). A smaller proportion of AA patients had active cancer (36.6% v. 40.3%, p = 0.73). Outcomes were generally inferior in the AA cohort, although these differences were not statistically significant. The rate of ICU admission was 41.5% in AA and 37.1% in non-AA (p=0.659). 34.5% of AA patients required intubation compared to 25.8% of non-AA patients (p=0.288). In our model, older age was the only variable that significantly increased the risk of death (standard hazard ratio SHR 1.05, p = 0.002). The risk of death was higher for AA patients (SHR 1.92, p=0.068) and males (SHR 1.62, p = 0.078) but did not meet statistical significance.
Discussion: COVID-19 outcomes were worse in the AA cancer population, but these differences did not meet statistical significance. Inferior outcomes for AA cancer patients were seen despite younger age and a smaller proportion of patients with active cancer. Our analysis focused on hospitalized patients, which would tend to select patients with similar disease severity. Notably, AA patients were significantly over-represented in our cohort (70% of hospitalizations compared to 14% of Michigan population). Our results suggest that racial disparities in outcomes for cancer patients with a SARS-CoV-2 infection may exist, but further study of larger, less selected populations is needed.
Citation Format: Steven S. Chang, Clara Hwang, Mohamed A. Elshaikh, Amy Tang, Christine M. Neslund-Dudas, Albert M. Levin, Laila M. Poisson, Benjamin A. Rybicki. Outcomes by race for cancer patients hospitalized with SARS-CoV-2 infection [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr S09-02.
Collapse
Affiliation(s)
| | | | | | - Amy Tang
- Henry Ford Cancer Institute, Detroit, MI
| | | | | | | | | |
Collapse
|
26
|
Darvishi P, Batchala PP, Patrie JT, Poisson LM, Lopes MB, Jain R, Fadul CE, Schiff D, Patel SH. Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes. AJNR Am J Neuroradiol 2020; 41:815-821. [PMID: 32327434 DOI: 10.3174/ajnr.a6511] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Accepted: 02/29/2020] [Indexed: 02/01/2023]
Abstract
BACKGROUND AND PURPOSE Despite the improved prognostic relevance of the 2016 WHO molecular-based classification of lower-grade gliomas, variability in clinical outcome persists within existing molecular subtypes. Our aim was to determine prognostically significant metrics on preoperative MR imaging for lower-grade gliomas within currently defined molecular categories. MATERIALS AND METHODS We undertook a retrospective analysis of 306 patients with lower-grade gliomas accrued from an institutional data base and The Cancer Genome Atlas. Two neuroradiologists in consensus analyzed preoperative MRIs of each lower-grade glioma to determine the following: tumor size, tumor location, number of involved lobes, corpus callosum involvement, hydrocephalus, midline shift, eloquent cortex involvement, ependymal extension, margins, contrast enhancement, and necrosis. Adjusted hazard ratios determined the association between MR imaging metrics and overall survival per molecular subtype, after adjustment for patient age, patient sex, World Health Organization grade, and surgical resection status. RESULTS For isocitrate dehydrogenase (IDH) wild-type lower-grade gliomas, tumor size (hazard ratio, 3.82; 95% CI, 1.94-7.75; P < .001), number of involved lobes (hazard ratio, 1.70; 95% CI, 1.28-2.27; P < .001), hydrocephalus (hazard ratio, 4.43; 95% CI, 1.12-17.54; P = .034), midline shift (hazard ratio, 1.16; 95% CI, 1.03-1.30; P = .013), margins (P = .031), and contrast enhancement (hazard ratio, 0.34; 95% CI, 0.13-0.90; P = .030) were associated with overall survival. For IDH-mutant 1p/19q-codeleted lower-grade gliomas, tumor size (hazard ratio, 2.85; 95% CI, 1.06-7.70; P = .039) and ependymal extension (hazard ratio, 6.34; 95% CI, 1.07-37.59; P = .042) were associated with overall survival. CONCLUSIONS MR imaging metrics offers prognostic information for patients with lower-grade gliomas within molecularly defined classes, with the greatest prognostic value for IDH wild-type lower-grade gliomas.
Collapse
Affiliation(s)
- P Darvishi
- From the Departments of Radiology and Medical Imaging (P.D., P.P.B., S.H.P.)
| | - P P Batchala
- From the Departments of Radiology and Medical Imaging (P.D., P.P.B., S.H.P.)
| | | | - L M Poisson
- Department of Public Health (L.M.P.), Henry Ford Health System, Detroit, Michigan
| | - M-B Lopes
- Pathology, Divisions of Neuropathology and Molecular Diagnostics (M.-B.L.)
| | - R Jain
- Departments of Radiology (R.J.) and Neurosurgery (R.J.), New York University School of Medicine, New York, New York
| | - C E Fadul
- Division of Neuro-Oncology (C.E.F., D.S.), University of Virginia Health System, Charlottesville, Virginia
| | - D Schiff
- Division of Neuro-Oncology (C.E.F., D.S.), University of Virginia Health System, Charlottesville, Virginia
| | - S H Patel
- From the Departments of Radiology and Medical Imaging (P.D., P.P.B., S.H.P.)
| |
Collapse
|
27
|
Abstract
PURPOSE OF REVIEW Real-world data (RWD) applications in healthcare that support learning health systems and pragmatic clinical trials are gaining momentum, largely due to legislation supporting real-world evidence (RWE) for drug approvals. Clinical notes are thought to be the cornerstone of RWD applications, particularly for conditions with limited effective treatments, extrapolation of treatments from other conditions, or heterogenous disease biology and clinical phenotypes. RECENT FINDINGS Here, we discuss current issues in applying RWD captured at the point-of-care and provide a framework for clinicians to engage in RWD collection. To achieve clinically meaningful results, RWD must be reliably captured using consistent terminology in the description of our patients. RWD complements traditional clinical trials and research by informing the generalizability of results, generating new hypotheses, and creating a large data network for scientific discovery. Effective clinician engagement in the development of RWD applications is necessary for continued progress in the field.
Collapse
Affiliation(s)
- James M Snyder
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA.
| | - Jacob A Pawloski
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA
| | - Laila M Poisson
- Department of Public Health Sciences, Hermelin Brain Tumor Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA
| |
Collapse
|
28
|
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 2019; 576:112-120. [PMID: 31748746 PMCID: PMC6897368 DOI: 10.1038/s41586-019-1775-1] [Citation(s) in RCA: 280] [Impact Index Per Article: 56.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Accepted: 10/01/2019] [Indexed: 12/15/2022]
Abstract
The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse glioma remain unclear1,2. Here we analysed temporally separated DNA-sequencing data and matched clinical annotation from 222 adult patients with glioma. By analysing mutations and copy numbers across the three major subtypes of diffuse glioma, we found that driver genes detected at the initial stage of disease were retained at recurrence, whereas there was little evidence of recurrence-specific gene alterations. Treatment with alkylating agents resulted in a hypermutator phenotype at different rates across the glioma subtypes, and hypermutation was not associated with differences in overall survival. Acquired aneuploidy was frequently detected in recurrent gliomas and was characterized by IDH mutation but without co-deletion of chromosome arms 1p/19q, and further converged with acquired alterations in the cell cycle and poor outcomes. The clonal architecture of each tumour remained similar over time, but the presence of subclonal selection was associated with decreased survival. Finally, there were no differences in the levels of immunoediting between initial and recurrent gliomas. Collectively, our results suggest that the strongest selective pressures occur during early glioma development and that current therapies shape this evolution in a largely stochastic manner.
Collapse
Affiliation(s)
- Floris P Barthel
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
- Department of Pathology, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Kevin C Johnson
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Frederick S Varn
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | | | - Georgette Tanner
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
| | - Emre Kocakavuk
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
- DKFZ Division of Translational Neurooncology at the West German Cancer Center, German Cancer Consortium Partner Site, University Hospital Essen, Essen, Germany
- Department of Neurosurgery, University Hospital Essen, Essen, Germany
| | - Kevin J Anderson
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Olajide Abiola
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Kenneth Aldape
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Kristin D Alfaro
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Donat Alpar
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
| | | | - David M Ashley
- Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, USA
| | - Pratiti Bandopadhayay
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Broad Institute, Cambridge, MA, USA
| | - Jill S Barnholtz-Sloan
- Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Rameen Beroukhim
- Broad Institute, Cambridge, MA, USA
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Christoph Bock
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | | | - Daniel J Brat
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Andrew R Brodbelt
- Department of Neurosurgery, University of Liverpool & Walton Centre NHS Trust, Liverpool, UK
| | - Alexander F Bruns
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
| | - Ketan R Bulsara
- Division of Neurosurgery, The University of Connecticut Health Center, Farmington, CT, USA
| | - Aruna Chakrabarty
- Department of Cellular and Molecular Pathology, Leeds Teaching Hospital NHS Trust, St James's University Hospital, Leeds, UK
| | - Arnab Chakravarti
- Department of Radiation Oncology, The Ohio State Comprehensive Cancer Center-Arthur G. James Cancer Hospital, Columbus, OH, USA
| | - Jeffrey H Chuang
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
- Department of Genetics and Genome Sciences, UConn Health, Farmington, CT, USA
| | - Elizabeth B Claus
- Yale University School of Public Health, New Haven, CT, USA
- Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA
| | - Elizabeth J Cochran
- Department of Pathology & Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Jennifer Connelly
- Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Joseph F Costello
- Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA
| | | | - Michael N Fletcher
- Division of Molecular Genetics, Heidelberg Center for Personalized Oncology, German Cancer Research Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Pim J French
- Department of Neurology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Hui K Gan
- Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia
- La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia
| | - Mark R Gilbert
- Neuro-Oncology Branch, National Institutes of Health, Bethesda, MD, USA
| | - Peter V Gould
- Anatomic Pathology Service, Hôpital de l'Enfant-Jésus, CHU de Québec-Université Laval, Quebec, Quebec, Canada
| | - Matthew R Grimmer
- Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA
| | - Antonio Iavarone
- Department of Neurology, Columbia University Medical Center, New York, NY, USA
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA
- Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA
| | - Azzam Ismail
- Department of Cellular and Molecular Pathology, Leeds Teaching Hospital NHS Trust, St James's University Hospital, Leeds, UK
| | - Michael D Jenkinson
- Department of Neurosurgery, University of Liverpool & Walton Centre NHS Trust, Liverpool, UK
| | - Mustafa Khasraw
- Cooperative Trials Group for Neuro-Oncology (COGNO) NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia
| | - Hoon Kim
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Mathilde C M Kouwenhoven
- Department of Neurology, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Peter S LaViolette
- Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Meihong Li
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Peter Lichter
- Division of Molecular Genetics, Heidelberg Center for Personalized Oncology, German Cancer Research Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Keith L Ligon
- Broad Institute, Cambridge, MA, USA
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Allison K Lowman
- Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Tathiane M Malta
- Department of Neurosurgery, Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI, USA
| | - Tali Mazor
- Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA
| | - Kerrie L McDonald
- Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - Annette M Molinaro
- Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA
| | - Do-Hyun Nam
- Department of Neurosurgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, South Korea
| | - Naema Nayyar
- Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA
| | - Ho Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
| | - Chew Yee Ngan
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - Simone P Niclou
- Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Johanna M Niers
- Department of Neurology, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Houtan Noushmehr
- Department of Neurosurgery, Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI, USA
| | - Javad Noorbakhsh
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
| | - D Ryan Ormond
- Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA
| | - Chul-Kee Park
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea
| | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI, USA
| | - Raul Rabadan
- Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA
- Department of Systems Biology, Columbia University, New York, NY, USA
| | - Bernhard Radlwimmer
- Division of Molecular Genetics, Heidelberg Center for Personalized Oncology, German Cancer Research Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ganesh Rao
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Guido Reifenberger
- Institute of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Jason K Sa
- Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, South Korea
| | - Michael Schuster
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
| | - Brian L Shaw
- Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA
| | - Susan C Short
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
| | - Peter A Sillevis Smitt
- Department of Neurology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Andrew E Sloan
- Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA
- Department of Neurosurgery, Case Western Reserve University, Cleveland, OH, USA
- Seidman Cancer Center and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA
| | - Marion Smits
- Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands
| | | | - Ghazaleh Tabatabai
- Interdiscplinary Division of Neuro-Oncology, Hertie Institute for Clinical Brain Research, DKTK Partner Site Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
| | - Erwin G Van Meir
- Department of Neurosurgery, School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | - Colin Watts
- Institute of Cancer Genome Sciences, Department of Neurosurgery, University of Birmingham, Birmingham, UK
| | - Michael Weller
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Pieter Wesseling
- Department of Pathology, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Bart A Westerman
- Department of Neurosurgery, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Georg Widhalm
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - Adelheid Woehrer
- Institute of Neurology, Medical University of Vienna, Vienna, Austria
| | - W K Alfred Yung
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Gelareh Zadeh
- Division of Neurosurgery, Department of Surgery, University Health Network, Toronto, Ontario, Canada
| | - Jason T Huse
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - John F De Groot
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Lucy F Stead
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
| | - Roel G W Verhaak
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
| |
Collapse
|
29
|
Check DK, Hutcheson KA, Poisson LM, Pocobelli G, Sakoda LC, Zaveri J, Chang SS, Chubak J. Factors associated with employment discontinuation among older and working age survivors of oropharyngeal cancer. Head Neck 2019; 41:3948-3959. [PMID: 31490588 DOI: 10.1002/hed.25943] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 07/11/2019] [Accepted: 08/15/2019] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Oropharyngeal cancer survivors experience difficulty returning to work after treatment. To better understand specific barriers to returning to work, we investigated factors associated with discontinuing employment among older and working-age survivors. METHODS The sample included 675 oropharyngeal cancer survivors (median: 6 years posttreatment) diagnosed from 2000 to 2013 and employed at diagnosis. Relative risk models were constructed to examine the independent associations of demographic and health factors, and symptom experiences per the MD Anderson Symptom Inventory - Head and Neck Module (MDASI-HN) with posttreatment employment, overall and by age (<60 years vs ≥60 years at survey). RESULTS Symptom interference was not statistically significantly associated with posttreatment employment status among respondents ≥60 years. Among working-age respondents <60 years, symptom interference was strongly associated with posttreatment employment. CONCLUSIONS Efforts to assess and lessen symptom burden in working-age survivors should be evaluated as approaches to support regaining core functions needed for continued employment.
Collapse
Affiliation(s)
- Devon K Check
- Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina
| | | | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan
| | - Gaia Pocobelli
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington
| | - Lori C Sakoda
- Kaiser Permanente Northern California Division of Research, Oakland, California
| | - Jhankruti Zaveri
- Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
| | - Steven S Chang
- Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan
| | - Jessica Chubak
- Kaiser Permanente Washington Health Research Institute, Seattle, Washington
| |
Collapse
|
30
|
Castro AV, Wells M, Asmaro K, Sabedot TS, Mosella MS, Malta TM, Nelson K, Snyder J, deCarvalho A, Mukherjee A, Chitale D, Robin A, Rosenblum M, Mikkelsen T, Poisson LM, Lee I, Walbert T, Bhan A, Kalkanis S, Rock J, Noushmehr H. P01.02 Serum-derived DNA methylation markers distinguish functional and invasiveness subtypes in patients harboring pituitary tumors. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Molecular profiling of circulating biomarkers released by tumors has a relevant clinical value in central nervous system (CNS) tumors, but its feasibility has not been investigated in pituitary tumors (PT) despite being the second common intraaxial tumors of the CNS (~15%). Although usually benign and slow-growing, they can be nonfunctioning and invade surrounding structures resulting in significant comorbidities. DNA methylation aberrations distinguish PT according to their functional status but their role in invasiveness is still unclear. Pre-surgical detection of clinically relevant molecular markers associated with tumor behavior can address current diagnostic and therapeutic challenges. We hypothesized that PT release cell-free DNA (cfDNA) into the bloodstream allowing for the profiling of epigenetic markers associated with relevant clinicopathological features.
MATERIAL AND METHODS
Genome-wide methylome profile of paired serum cfDNA (EPIC array) and tissue from 13 patients with pituitary macroadenomas (9 males; median age: 62; 9 NFPT, 6 invasive) and 3 controls serum (patients with epilepsy).
RESULTS
Unsupervised analysis of the serum methylome from patients harboring PT was distinct from controls and other diseases (hypopituitarism, glioma and colorectal cancer) and supervised analysis (Wilcoxon Rank-sum Test) identified significant differentially methylated probes (DMP) that segregated PT from control serum specimens. Nonfunctioning and invasive-specific DMPs identified in the serum also defined functional, and less prominently invasive status, in the tissue of an independent cohort of PT.
CONCLUSION
This is the first study to show the feasibility to profile the methylome in the serum of patients with PT using cfDNA. In addition, we identified unique methylation signatures that distinguished PT according to functional and invasiveness subtypes. These results underpin the potential role of methylation profile and liquid biopsy as a noninvasive approach to assess clinically relevant molecular features in the serum of patients harboring PT.
Collapse
Affiliation(s)
- A V Castro
- Henry Ford Health System, Detroit, MI, United States
| | - M Wells
- Henry Ford Health System, Detroit, MI, United States
| | - K Asmaro
- Henry Ford Health System, Detroit, MI, United States
| | - T S Sabedot
- Henry Ford Health System, Detroit, MI, United States
| | - M S Mosella
- Henry Ford Health System, Detroit, MI, United States
| | - T M Malta
- Henry Ford Health System, Detroit, MI, United States
| | - K Nelson
- Henry Ford Health System, Detroit, MI, United States
| | - J Snyder
- Henry Ford Health System, Detroit, MI, United States
| | - A deCarvalho
- Henry Ford Health System, Detroit, MI, United States
| | - A Mukherjee
- Henry Ford Health System, Detroit, MI, United States
| | - D Chitale
- Henry Ford Health System, Detroit, MI, United States
| | - A Robin
- Henry Ford Health System, Detroit, MI, United States
| | - M Rosenblum
- Henry Ford Health System, Detroit, MI, United States
| | - T Mikkelsen
- Henry Ford Health System, Detroit, MI, United States
| | - L M Poisson
- Henry Ford Health System, Detroit, MI, United States
| | - I Lee
- Henry Ford Health System, Detroit, MI, United States
| | - T Walbert
- Henry Ford Health System, Detroit, MI, United States
| | - A Bhan
- Henry Ford Health System, Detroit, MI, United States
| | - S Kalkanis
- Henry Ford Health System, Detroit, MI, United States
| | - J Rock
- Henry Ford Health System, Detroit, MI, United States
| | - H Noushmehr
- Henry Ford Health System, Detroit, MI, United States
| |
Collapse
|
31
|
Noushmehr H, Sabedot TS, Malta TM, Nelson KK, Snyder J, Wells M, Mosella MS, deCarvalho AC, Asmaro K, Scarpace L, Robin AM, Rosenblum ML, Mikkelsen T, Rock J, Walbert T, Lee I, Poisson LM, Kalkanis SN, Castro AV. Abstract LB-234: Pre-surgical identification of diagnostic, prognostic and predictive DNA methylation-based markers in serum (liquid biopsy) of patients harboring gliomas. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-lb-234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Central nervous system-related tumors release tumoral material into circulating blood and the cerebrospinal fluid (e.g. cell free DNA). The sampling of these biofluids, i.e. liquid biopsy (LB), may offer an opportunity for diagnosis, prognostication and response prediction in a constantly evolving and biologically and prognostically heterogeneous tumor, such as glioma, in real-time. In glioma-tumor tissue, genome-wide DNA methylation profiling has shown that epigenetic abnormalities play significant biological and clinical roles, making DNA methylome profiling attractive for LB application in these tumors. Thus far, studies of epigenetic LB (eLB) focused on targeted markers which have shown low sensitivity; however, this can be potentially circumvented by a comprehensive genome-wide CpG methylation profiling. Herein, we profiled the genome-wide CpG methylation landscape of matching serum/tissue from 22 patients who received surgical resection for a glioma diagnosis (15 IDH-mutant and 7 IDH-wildtype) and 4 who received surgical resection of the brain for a non-tumor brain related disease. We identified 199 glioma specific DNA methylation-serum based markers (Wilcoxon Rank Sum test, p-value < 0.001) that differentiated glioma from non-tumor brain tissues (diagnostic eLB). These eLB diagnostic markers were found to be enriched for CpG islands and depleted for open seas and shores. Interestingly, CpG methylation of MYC and CD34 promoters, previously described in the tissue, were detectable in the serum of glioma patients as part of the 199 CpG eLB signature. We also identified 987 eLB markers (Wilcoxon Rank Sum test, p-value < 0.01) that discriminated patients with IDH-mutant from IDH-wildtype (prognostic eLB). Among the initial cohort, comprised by 4 MGMT-unmethylated and 18 MGMT-methylated gliomas, we also identified 428 specific eLB markers that discriminated the MGMT status among the patients (predictive eLB). Harnessing DNA methylation data of The Cancer Genome Atlas (TCGA) consortium, derived from 10,000 primary and untreated tumor tissue samples, spanning 33 cancer types, we found our three eLB signatures (diagnostic, prognostic and predictive) to be highly specific to gliomas. Our results suggest that serum eLB profiling may be useful as a surrogate or complementary for tissue-based approach for diagnosis, prognostication and treatment prediction of gliomas. In addition, our eLB signatures can be applied as a real-time non-invasive approach to improve detection of glioma progression and recurrence. Once validated, the application of the eLB panels discovered in this study have the potential to significantly and positively improve the pre- and post-surgical quality of care for patients harboring gliomas.
Citation Format: Houtan Noushmehr, Thais S. Sabedot, Tathiane M. Malta, Kevin K. Nelson, James Snyder, Michael Wells, Maritza S. Mosella, Ana C. deCarvalho, Karam Asmaro, Lisa Scarpace, Adam M. Robin, Mark L. Rosenblum, Tom Mikkelsen, Jack Rock, Tobias Walbert, Ian Lee, Laila M. Poisson, Steven N. Kalkanis, Ana V. Castro. Pre-surgical identification of diagnostic, prognostic and predictive DNA methylation-based markers in serum (liquid biopsy) of patients harboring gliomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-234.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Jack Rock
- Henry Ford Health System, Detroit, MI
| | | | - Ian Lee
- Henry Ford Health System, Detroit, MI
| | | | | | | |
Collapse
|
32
|
Snyder J, Poisson LM, Noushmehr H, Castro AV, deCarvalho AC, Robin A, Mukherjee A, Lee I, Walbert T. Clinical and research applications of a brain tumor tissue bank in the age of precision medicine. Per Med 2019; 16:145-156. [PMID: 30816054 PMCID: PMC6598053 DOI: 10.2217/pme-2018-0102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Marked progress has been made recently in the treatment of patients with central nervous system (CNS) tumors, especially gliomas. However, because of the relative rarity of these tumors compared with other malignancies, advances in the molecular/genetic analysis leading to future targeted treatments rely on systematic, organized tissue banking. Several large multi-institutional efforts have utilized major tissue banks that have yielded valuable information that may lead to a better understanding of the pathogenesis of CNS tumors. This manuscript portrays best practices for the establishment and maintenance of a well-organized CNS tumor bank. In addition, annotation for clinical and research needs is explained. The potential benefits to clinical care, as well as basic science and translational research are also described.
Collapse
Affiliation(s)
- James Snyder
- Department of Neurology, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA.,Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Laila M Poisson
- Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Houtan Noushmehr
- Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Ana V Castro
- Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Ana C deCarvalho
- Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Adam Robin
- Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Abir Mukherjee
- Department of Pathology, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Ian Lee
- Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| | - Tobias Walbert
- Department of Neurology, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA.,Department of Neurosurgery, 2799 W Grand Blvd, Henry Ford Health System, Detroit, MI 48202 USA
| |
Collapse
|
33
|
Halani SH, Yousefi S, Velazquez Vega J, Rossi MR, Zhao Z, Amrollahi F, Holder CA, Baxter-Stoltzfus A, Eschbacher J, Griffith B, Olson JJ, Jiang T, Yates JR, Eberhart CG, Poisson LM, Cooper LAD, Brat DJ. Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2018; 2:24. [PMID: 30417117 PMCID: PMC6219505 DOI: 10.1038/s41698-018-0067-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Revised: 09/18/2018] [Accepted: 09/24/2018] [Indexed: 12/22/2022] Open
Abstract
Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers for stratifying risk. We utilized machine-learning approaches with genomic data from The Cancer Genome Atlas to objectively identify molecular factors associated with clinical outcomes of oligodendroglioma and extended these findings to study signaling pathways implicated in oncogenesis and clinical endpoints associated with glioma progression. Our multi-faceted computational approach uncovered key genetic alterations associated with disease progression and shorter survival in oligodendroglioma and specifically identified Notch pathway inactivation and PI3K pathway activation as the most strongly associated with MRI and pathology findings of advanced disease and poor clinical outcome. Our findings that Notch pathway inactivation and PI3K pathway activation are associated with advanced disease and survival risk will pave the way for clinically relevant markers of disease progression and therapeutic targets to improve clinical outcomes. Furthermore, our approach demonstrates the strength of machine learning and computational methods for identifying genetic events critical to disease progression in the era of big data and precision medicine.
Collapse
Affiliation(s)
| | - Safoora Yousefi
- Department of Biomedical Informatics, Emory University, Atlanta, GA USA
| | - Jose Velazquez Vega
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA USA
| | - Michael R. Rossi
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA USA
| | - Zheng Zhao
- Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China
| | - Fatemeh Amrollahi
- Department of Biomedical Informatics, Emory University, Atlanta, GA USA
| | - Chad A. Holder
- Department of Radiology, Emory University, Atlanta, GA USA
| | | | - Jennifer Eschbacher
- Department of Neuropathology, Barrow Neurological Institute, Phoenix, AZ USA
| | - Brent Griffith
- Department of Radiology, Henry Ford Health System, Detroit, MI USA
- Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI USA
| | - Jeffrey J. Olson
- Emory University School of Medicine, Atlanta, GA USA
- Department of Neurosurgery, Emory University, Atlanta, GA USA
- Winship Cancer Institute, Emory University, Atlanta, GA USA
| | - Tao Jiang
- Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China
| | - Joseph R. Yates
- Divisions of Pathology, Ophthalmology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - Charles G. Eberhart
- Divisions of Pathology, Ophthalmology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD USA
| | - Laila M. Poisson
- Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI USA
- Department of Public Health Sciences, Henry Ford Hospital Systems, Detroit, MI USA
| | - Lee A. D. Cooper
- Emory University School of Medicine, Atlanta, GA USA
- Department of Biomedical Informatics, Emory University, Atlanta, GA USA
- Winship Cancer Institute, Emory University, Atlanta, GA USA
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA USA
| | - Daniel J. Brat
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL USA
| |
Collapse
|
34
|
Wu CC, Jain R, Radmanesh A, Poisson LM, Guo WY, Zagzag D, Snuderl M, Placantonakis DG, Golfinos J, Chi AS. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. AJNR Am J Neuroradiol 2018; 39:1814-1820. [PMID: 30190259 DOI: 10.3174/ajnr.a5794] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Accepted: 07/02/2018] [Indexed: 12/26/2022]
Abstract
BACKGROUND AND PURPOSE Few studies have shown MR imaging features and ADC correlating with molecular markers and survival in patients with glioma. Our purpose was to correlate MR imaging features and ADC with molecular subtyping and survival in adult diffuse gliomas. MATERIALS AND METHODS Presurgical MRIs and ADC maps of 131 patients with diffuse gliomas and available molecular and survival data from The Cancer Genome Atlas were reviewed. MR imaging features, ADC (obtained by ROIs within the lowest ADC area), and mean relative ADC values were evaluated to predict isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion status, MGMT promoter methylation, and overall survival. RESULTS IDH wild-type gliomas tended to exhibit enhancement, necrosis, and edema; >50% enhancing area (P < .001); absence of a cystic area (P = .013); and lower mean relative ADC (median, 1.1 versus 1.6; P < .001) than IDH-mutant gliomas. By means of a cutoff value of 1.08 for mean relative ADC, IDH-mutant and IDH wild-type gliomas with lower mean relative ADC (<1.08) had poorer survival than those with higher mean relative ADC (median survival time, 24.2 months; 95% CI, 0.0-54.9 months versus 62.0 months; P = .003; and median survival time, 10.4 months; 95% CI, 4.4-16.4 months versus 17.7 months; 95% CI, 11.6-23.7 months; P = .041, respectively), regardless of World Health Organization grade. Median survival of those with IDH-mutant glioma with low mean relative ADC was not significantly different from that in those with IDH wild-type glioma. Other MR imaging features were not statistically significant predictors of survival. CONCLUSIONS IDH wild-type glioma showed lower ADC values, which also correlated with poor survival in both IDH-mutant and IDH wild-type gliomas, irrespective of histologic grade. A subgroup with IDH-mutant gliomas with lower ADC had dismal survival similar to that of those with IDH wild-type gliomas.
Collapse
Affiliation(s)
- C-C Wu
- From the Department of Radiology (C.-C.W., W.-Y.G.), Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
- School of Medicine (C.-C.W., W.-Y.G.), National Yang-Ming University, Taipei, Taiwan, Republic of China
- Departments of Radiology (C.-C.W., R.J., A.R.)
| | - R Jain
- Departments of Radiology (C.-C.W., R.J., A.R.)
- Neurosurgery (R.J., D.P., J.G.)
| | - A Radmanesh
- Departments of Radiology (C.-C.W., R.J., A.R.)
| | - L M Poisson
- Department of Public Health Sciences and Hermelin Brain Tumor Center (L.M.P.), Henry Ford Hospital, Detroit, Michigan
| | - W-Y Guo
- From the Department of Radiology (C.-C.W., W.-Y.G.), Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
- School of Medicine (C.-C.W., W.-Y.G.), National Yang-Ming University, Taipei, Taiwan, Republic of China
| | - D Zagzag
- Pathology (D.Z., M.S.), NYU School of Medicine, New York, New York
| | - M Snuderl
- Pathology (D.Z., M.S.), NYU School of Medicine, New York, New York
| | | | | | - A S Chi
- Neuro-Oncology Program (A.S.C.), Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine and Langone Health, New York, New York
| |
Collapse
|
35
|
Berezovsky AD, Transou AD, Irtenkauf SM, Hasselbach LA, Koeman J, Kim H, Verhaak RG, Mikkelsen T, Poisson LM, deCarvalho AC. Abstract 3491: Heterogeneous extrachromosomal amplification of mutant PDGFRA is associated with an aggressive phenotype in glioblastoma. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background & Objective: Receptor tyrosine kinase (RTK) signaling is altered in over 80% of glioblastoma (GBM) cases, frequently through gene amplification. About 14% of GBMs carry amplification in the gene coding for platelet-derived growth factor receptor A (PDGFRA), according to TCGA. PDGFRA plays a key role in brain development and is associated with GBM proneural (PN) subtype. Despite the frequency of oncogenic RTK signaling in GBMs, RTK inhibitors have not yet achieved sufficient efficacy in clinical trials to earn FDA approval. Imatinib, a multi-kinase inhibitor that targets PDGFRA, has not shown efficacy in earlier clinical trials for GBM, in which amplification status was not an inclusion criteria. It has been reported that treatment of GBMs carrying extrachromosomal (ecDNA) amplification with EGFR inhibitors leads to a decrease in ecDNA copy number as a mechanism of resistance. Here, our objective was to assess the heterogeneity of ecDNA PDGFRA amplification in a newly diagnosed PN GBM tumor (HF3253), and to evaluate whether similar modulation of ecDNA copy number could be attained by Imatinib treatment of patient-derived xenografts (PDX). Experimental Approaches & Results: PDGFRA amplification was detected by low pass whole genome sequencing and confirmed to be extrachromosomal by fluorescent in situ hybridization (FISH) in metaphase spreads using PDGFRA and centromere 4 labeled DNA probes. The amplified PDGFRA also harbored a novel missense mutation corresponding to the extracellular domain. PDGFRA FISH signals/number ranged from 3 to 100 in the HF3253 samples, with high signal (> 20) evident in 67%, 39%, and 43% and low amplification signal (6 < x < 9) evident in only 0%, 6%, and 19% of nuclei from biopsy, neurosphere, and xenograft respectively. HF3253 neurospheres were orthotopically implanted into the brains of immunocompromised nude mice. Imatinib mesylate was administered by oral gavage at a 75 mg/kg/day dosage in 5-day cycles with 2-day drug holiday intervals, starting 2 weeks post implant. Control mice received vehicle gavage under the same schedule. Mice were monitored daily and sacrificed on the basis of weight loss or neurological symptoms. HF3253 PDX treated with Imatinib mesylate did not have a significant survival advantage (median survival: 47.2 days) relative to control mice (median survival: 45.8 days; log rank test p value = 0.7825). The untreated and treated PDXs exhibited high levels of phospho-PDGFRA by IHC. Two independent in vitro dose response assays showed no difference in the IC50 for Imatinib between PDGFRA positive and negative GBM neurospheres: (9.447 µM, 8.384 µM) and (8.972 µM, 6.896 µM). Conclusions: We have developed a patient derived model of glioblastoma that retains ecDNA PDGFRA amplification and high levels of expression and RTK activation. Although PDGFRA is a driver of malignancy, our results show that better inhibitors are needed.
Citation Format: Artem D. Berezovsky, Andrea D. Transou, Susan M. Irtenkauf, Laura A. Hasselbach, Julie Koeman, Hoon Kim, Roel G. Verhaak, Tom Mikkelsen, Laila M. Poisson, Ana C. deCarvalho. Heterogeneous extrachromosomal amplification of mutant PDGFRA is associated with an aggressive phenotype in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3491.
Collapse
Affiliation(s)
| | | | | | | | | | - Hoon Kim
- 3The Jackson Laboratory for Genomic Medicine, Farmington, CT
| | - Roel G. Verhaak
- 3The Jackson Laboratory for Genomic Medicine, Farmington, CT
| | | | | | | |
Collapse
|
36
|
Chang P, Grinband J, Weinberg BD, Bardis M, Khy M, Cadena G, Su MY, Cha S, Filippi CG, Bota D, Baldi P, Poisson LM, Jain R, Chow D. Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. AJNR Am J Neuroradiol 2018; 39:1201-1207. [PMID: 29748206 DOI: 10.3174/ajnr.a5667] [Citation(s) in RCA: 228] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 03/20/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND PURPOSE The World Health Organization has recently placed new emphasis on the integration of genetic information for gliomas. While tissue sampling remains the criterion standard, noninvasive imaging techniques may provide complimentary insight into clinically relevant genetic mutations. Our aim was to train a convolutional neural network to independently predict underlying molecular genetic mutation status in gliomas with high accuracy and identify the most predictive imaging features for each mutation. MATERIALS AND METHODS MR imaging data and molecular information were retrospectively obtained from The Cancer Imaging Archives for 259 patients with either low- or high-grade gliomas. A convolutional neural network was trained to classify isocitrate dehydrogenase 1 (IDH1) mutation status, 1p/19q codeletion, and O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status. Principal component analysis of the final convolutional neural network layer was used to extract the key imaging features critical for successful classification. RESULTS Classification had high accuracy: IDH1 mutation status, 94%; 1p/19q codeletion, 92%; and MGMT promotor methylation status, 83%. Each genetic category was also associated with distinctive imaging features such as definition of tumor margins, T1 and FLAIR suppression, extent of edema, extent of necrosis, and textural features. CONCLUSIONS Our results indicate that for The Cancer Imaging Archives dataset, machine-learning approaches allow classification of individual genetic mutations of both low- and high-grade gliomas. We show that relevant MR imaging features acquired from an added dimensionality-reduction technique demonstrate that neural networks are capable of learning key imaging components without prior feature selection or human-directed training.
Collapse
Affiliation(s)
- P Chang
- From the Department of Radiology (P.C., S.C.), University of California, San Francisco, San Francisco, California
| | - J Grinband
- Department of Radiology (J.G.), Columbia University, New York, New York
| | - B D Weinberg
- Department of Radiology (B.D.W.), Emory University School of Medicine, Atlanta, Georgia
| | - M Bardis
- Departments of Radiology (M.B., M.K., M.-Y.S., D.C.)
| | - M Khy
- Departments of Radiology (M.B., M.K., M.-Y.S., D.C.)
| | | | - M-Y Su
- Departments of Radiology (M.B., M.K., M.-Y.S., D.C.)
| | - S Cha
- From the Department of Radiology (P.C., S.C.), University of California, San Francisco, San Francisco, California
| | - C G Filippi
- Department of Radiology (C.G.F.), North Shore University Hospital, Long Island, New York
| | | | - P Baldi
- School of Information and Computer Sciences (P.B.), University of California, Irvine, Irvine, California
| | - L M Poisson
- Department of Public Health Sciences (L.M.P.), Henry Ford Health System, Detroit, Michigan
| | - R Jain
- Departments of Radiology and Neurosurgery (R.J.), New York University, New York, New York
| | - D Chow
- Departments of Radiology (M.B., M.K., M.-Y.S., D.C.)
| |
Collapse
|
37
|
Griffith B, Capobres T, Patel SC, Marin H, Katramados A, Poisson LM. CSF Pressure Change in Relation to Opening Pressure and CSF Volume Removed. AJNR Am J Neuroradiol 2018; 39:1185-1190. [PMID: 29724759 DOI: 10.3174/ajnr.a5642] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Accepted: 02/24/2018] [Indexed: 01/03/2023]
Abstract
BACKGROUND AND PURPOSE Idiopathic intracranial hypertension is a complex neurologic disorder resulting from increased intracranial pressure. Our aim was to determine whether a correlation exists between the CSF pressure-volume relationship, specifically the craniospinal elastance and pressure-volume index, in patients with idiopathic intracranial hypertension and whether opening pressure affects this relationship. MATERIALS AND METHODS Lumbar punctures performed for suspected idiopathic intracranial hypertension from 2006 to 2017 were identified. Opening and closing pressures, CSF volume removed, and clinical diagnosis of idiopathic intracranial hypertension were obtained from the medical records. The craniospinal elastance (pressure change per milliliter of CSF removed) and pressure-volume index were calculated, and the Pearson correlation coefficients between both the craniospinal elastance and pressure-volume index and opening pressure were determined. Linear regression models of craniospinal elastance and the pressure-volume index and interaction terms with opening pressure were assessed for covariate influence on this association. RESULTS One hundred sixteen patients were included in the final analysis. The mean craniospinal elastance according to opening pressure group was 0.52 ± 0.18 for <20 cm H2O, 0.57 ± 0.20 for 20-29 cm H2O, 0.91 ± 0.28 for 30-39 cm H2O, and 1.20 ± 0.25 for ≥40 cm H2O. There was a positive linear association between opening pressure and craniospinal elastance with a 0.28 cm H2O/mL increase in craniospinal elastance (standard error = 0.03, P < .001) for every 10 cm H2O increase in opening pressure. Of the covariables analyzed, only age older than 50 years and total volume of CSF removed affected this association. CONCLUSIONS As opening pressure increases, the craniospinal elastance increases in a linear fashion while the pressure-volume index decreases. Further studies are needed to determine whether these changes relate to the underlying pathophysiology of idiopathic intracranial hypertension or simply represent established CSF volume pressure dynamics.
Collapse
Affiliation(s)
- B Griffith
- From the Departments of Radiology (B.G., T.C., S.C.P., H.M.)
| | - T Capobres
- From the Departments of Radiology (B.G., T.C., S.C.P., H.M.)
| | - S C Patel
- From the Departments of Radiology (B.G., T.C., S.C.P., H.M.)
| | - H Marin
- From the Departments of Radiology (B.G., T.C., S.C.P., H.M.)
| | | | | |
Collapse
|
38
|
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 2018; 173:400-416.e11. [PMID: 29625055 PMCID: PMC6066282 DOI: 10.1016/j.cell.2018.02.052] [Citation(s) in RCA: 1819] [Impact Index Per Article: 303.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 11/11/2017] [Accepted: 02/20/2018] [Indexed: 02/06/2023]
Abstract
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale.
Collapse
Affiliation(s)
- Jianfang Liu
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA
| | | | - Katherine A Hoadley
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Laila M Poisson
- Henry Ford Cancer Institute and Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
| | - Alexander J Lazar
- Departments of Pathology, Genomic Medicine, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Andrew D Cherniack
- The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Albert J Kovatich
- Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University/Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
| | | | - Douglas A Levine
- Division of Gynecologic Oncology, Department of OB/GYN, NYU Langone Medical Center, New York, NY 10016, USA
| | - Adrian V Lee
- Department of Pharmacology and Chemical Biology and Human Genetics, University of Pittsburgh, Women's Cancer Research Center, UPMC Hillman Cancer Center and Magee-Womens Research Institute, Pittsburgh, PA 15213, USA
| | | | - Denise M Wolf
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Craig D Shriver
- Murtha Cancer Center, Uniformed Services University/Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
| | | | - Hai Hu
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA.
| |
Collapse
|
39
|
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 2018. [PMID: 29625055 DOI: 10.1016/j.cell.2018.02.052]] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale.
Collapse
Affiliation(s)
- Jianfang Liu
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA
| | | | - Katherine A Hoadley
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Laila M Poisson
- Henry Ford Cancer Institute and Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
| | - Alexander J Lazar
- Departments of Pathology, Genomic Medicine, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Andrew D Cherniack
- The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Albert J Kovatich
- Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University/Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
| | | | - Douglas A Levine
- Division of Gynecologic Oncology, Department of OB/GYN, NYU Langone Medical Center, New York, NY 10016, USA
| | - Adrian V Lee
- Department of Pharmacology and Chemical Biology and Human Genetics, University of Pittsburgh, Women's Cancer Research Center, UPMC Hillman Cancer Center and Magee-Womens Research Institute, Pittsburgh, PA 15213, USA
| | | | - Denise M Wolf
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Craig D Shriver
- Murtha Cancer Center, Uniformed Services University/Walter Reed National Military Medical Center, Bethesda, MD 20889, USA
| | | | - Hai Hu
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA.
| |
Collapse
|
40
|
Jain R, Poisson LM, Littig I, Neto L, Wu CC, Ng V, Patel SH, Snuderl M, Zagzag D, Golfinos J, Chi AS. NIMG-33. CORRELATION BETWEEN IDH MUTATION STATUS, PATIENT SURVIVAL, AND BLOOD VOLUME ESTIMATES IN DIFFUSE GLIOMAS: A TCGA/TCIA PROJECT. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res 2017; 23:6078-6085. [PMID: 28751449 DOI: 10.1158/1078-0432.ccr-17-0560] [Citation(s) in RCA: 231] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 05/11/2017] [Accepted: 07/19/2017] [Indexed: 11/16/2022]
Abstract
Purpose: Lower-grade gliomas (WHO grade II/III) have been classified into clinically relevant molecular subtypes based on IDH and 1p/19q mutation status. The purpose was to investigate whether T2/FLAIR MRI features could distinguish between lower-grade glioma molecular subtypes.Experimental Design: MRI scans from the TCGA/TCIA lower grade glioma database (n = 125) were evaluated by two independent neuroradiologists to assess (i) presence/absence of homogenous signal on T2WI; (ii) presence/absence of "T2-FLAIR mismatch" sign; (iii) sharp or indistinct lesion margins; and (iv) presence/absence of peritumoral edema. Metrics with moderate-substantial agreement underwent consensus review and were correlated with glioma molecular subtypes. Somatic mutation, DNA copy number, DNA methylation, gene expression, and protein array data from the TCGA lower-grade glioma database were analyzed for molecular-radiographic associations. A separate institutional cohort (n = 82) was analyzed to validate the T2-FLAIR mismatch sign.Results: Among TCGA/TCIA cases, interreader agreement was calculated for lesion homogeneity [κ = 0.234 (0.111-0.358)], T2-FLAIR mismatch sign [κ = 0.728 (0.538-0.918)], lesion margins [κ = 0.292 (0.135-0.449)], and peritumoral edema [κ = 0.173 (0.096-0.250)]. All 15 cases that were positive for the T2-FLAIR mismatch sign were IDH-mutant, 1p/19q non-codeleted tumors (P < 0.0001; PPV = 100%, NPV = 54%). Analysis of the validation cohort demonstrated substantial interreader agreement for the T2-FLAIR mismatch sign [κ = 0.747 (0.536-0.958)]; all 10 cases positive for the T2-FLAIR mismatch sign were IDH-mutant, 1p/19q non-codeleted tumors (P < 0.00001; PPV = 100%, NPV = 76%).Conclusions: Among lower-grade gliomas, T2-FLAIR mismatch sign represents a highly specific imaging biomarker for the IDH-mutant, 1p/19q non-codeleted molecular subtype. Clin Cancer Res; 23(20); 6078-85. ©2017 AACR.
Collapse
Affiliation(s)
- Sohil H Patel
- Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia.
| | - Laila M Poisson
- Department of Public Health, Henry Ford Health System, Detroit, Michigan
| | - Daniel J Brat
- Department of Pathology and Laboratory Medicine, Winship Cancer Institute at Emory University, Atlanta, Georgia
| | - Yueren Zhou
- Department of Public Health, Henry Ford Health System, Detroit, Michigan
| | - Lee Cooper
- Department of Biomedical Informatics, Emory School of Medicine, Atlanta, Georgia
- Department of Biomedical Engineering, Georgia Institute of Technology/Emory University School of Medicine, Atlanta, Georgia
| | - Matija Snuderl
- Department of Pathology, NYU Langone Medical Center, New York, New York
| | - Cheddhi Thomas
- Department of Pathology, NYU Langone Medical Center, New York, New York
| | - Ana M Franceschi
- Department of Radiology, NYU Langone Medical Center, New York, New York
| | - Brent Griffith
- Department of Radiology, Henry Ford Health System, Detroit, Michigan
| | - Adam E Flanders
- Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - John G Golfinos
- Department of Neurosurgery, NYU Langone Medical Center, New York, New York
| | - Andrew S Chi
- Department of Neurosurgery, NYU Langone Medical Center, New York, New York
- Division of Neuro-Oncology, NYU Langone Medical Center, New York, New York
| | - Rajan Jain
- Department of Radiology, NYU Langone Medical Center, New York, New York.
- Department of Neurosurgery, NYU Langone Medical Center, New York, New York
| |
Collapse
|
42
|
Poisson LM, Mikkelsen T, deCarvalho AC. Abstract A08: Neurosphere culture captures the clinical and molecular diversity of glioblastoma tumors. Clin Cancer Res 2016. [DOI: 10.1158/1557-3265.pdx16-a08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma (GBM), a WHO grade IV astrocytoma, is the most prevalent and aggressive primary central nervous system tumor, characterized by poor response to standard post-resection radiation and cytotoxic therapy, resulting in dismal prognosis, with a 2 year survival rate around 20%. Culturing dissociated cells from fresh GBM specimens in medium formulated for the selection and expansion of neural stem cells (NSC) from mammalian brain favors the growth of floating multicellular spheroids, referred to as neurospheres (NS), enriched in cancer stem-like cells. NSs have become a frequently used model for in vitro studies, and for implant in immunocompromised mice for the development of orthotopic GBM patient-derived xenografts (PDXs). These success rates in establishing long term neurosphere cultures from GBMs has been reported to be between 30 and 70%. It is important to assess any possible bias which might result if there were differences in the likelihood of GBM tumors forming neurospheres based on clinical characteristics or molecular profile. The goal of this study is to determine to what extent GBM transcriptional subtypes and driver genomic alterations are represented in neurosphere cultures and to identify clinical correlates contributing to the success (NS(+)) or failure (NS(-)) to obtain long term neurosphere cultures from fresh GBM tissue.
Samples from 145 fresh GBM surgical specimens containing viable non-necrotic tissue were dissociated and subjected to neurosphere culture for a minimum of 2 months. Of these, 103 were newly diagnosed, 39 recurrent, and 3 secondary GBMs, which progress from a lower grade tumor. The rate of neurosphere formation was not different between newly diagnosed (43%) and recurrent (44%) tumors (Fisher's Exact Test (FET), p>0.999). Among 9 pairs of matched newly diagnosed NS(+) and recurrent tumors, 6 retained NS(+) status upon recurrence and 3 switched to NP(-). The 3 secondary GBM samples, which progressed from lower grade tumors, were NS(-). For newly diagnosed GBMs, NS formation was significantly correlated with shorter time to progression (log-rank p=0.0147), but not with overall patient survival (log-rank p=0.163). There is a tendency for NS(+) tumors to have an increased risk of death, after adjusting for age at diagnosis (HR: 1.49, 95% CI: (0.95, 2.34); log-rank p=0.0830). Patient age at diagnosis, gender and race did not influence the proportion of NS(+) tumors . Mutations in IDH1 and promoter methylation leading to silencing of the MGMT gene have both been presented as biomarkers of less aggressive disease. The 6 GBMs harboring a mutation in IDH1 were NP(-). MGMT promoter methylation status did not correlate with neurosphere formation. Thirty three of the newly diagnosed GBMs were profiled by the TCGA GBM project. Neurospheres were established for 15 (45.4%) of these tumor samples. NP(+) tumors were distributed among all 4 transcriptional subtypes, with classical and non-GCIMP proneural tumors showing the highest success rate. Since most individual genomic mutations and copy number variations (CNVs) occur at a low frequency in GBMs, we investigated the representation of genes most frequently altered in a subset of the neurospheres, by exome and low pass whole genome DNA sequencing. Among the genes altered in the panel were: CDKN2A, EGFR, PTEN, TP53, CDK4, PDGFRA, NF1, PIK3CA, PIK3R1, RB1, MDM2, MDM4, ATRX, TERT, STAG2, MET, HDAC9 and MYC. Only 6 GBMs harboring IDH1 mutation were included, and this was the only genomic abnormality occurring in over 4% of GBMs that was not represented in the neurosphere panel profiled.
We conclude that culturing neurospheres is a valid strategy to capture the clinical and molecular diversity associated with GBM tumors, but further comparisons of gene expression, epigenetic regulation, and other propagation methods for NS(-) and NS(+) tumors are granted.
Citation Format: Laila M. Poisson, Tom Mikkelsen, Ana C. deCarvalho. Neurosphere culture captures the clinical and molecular diversity of glioblastoma tumors. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A08.
Collapse
|
43
|
Poisson LM, Suhail H, Singh J, Datta I, Denic A, Labuzek K, Hoda MN, Shankar A, Kumar A, Cerghet M, Elias S, Mohney RP, Rodriguez M, Rattan R, Mangalam AK, Giri S. Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. J Biol Chem 2015; 290:30697-712. [PMID: 26546682 DOI: 10.1074/jbc.m115.679068] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Indexed: 12/20/2022] Open
Abstract
We performed untargeted metabolomics in plasma of B6 mice with experimental autoimmune encephalitis (EAE) at the chronic phase of the disease in search of an altered metabolic pathway(s). Of 324 metabolites measured, 100 metabolites that mapped to various pathways (mainly lipids) linked to mitochondrial function, inflammation, and membrane stability were observed to be significantly altered between EAE and control (p < 0.05, false discovery rate <0.10). Bioinformatics analysis revealed six metabolic pathways being impacted and altered in EAE, including α-linolenic acid and linoleic acid metabolism (PUFA). The metabolites of PUFAs, including ω-3 and ω-6 fatty acids, are commonly decreased in mouse models of multiple sclerosis (MS) and in patients with MS. Daily oral administration of resolvin D1, a downstream metabolite of ω-3, decreased disease progression by suppressing autoreactive T cells and inducing an M2 phenotype of monocytes/macrophages and resident brain microglial cells. This study provides a proof of principle for the application of metabolomics to identify an endogenous metabolite(s) possessing drug-like properties, which is assessed for therapy in preclinical mouse models of MS.
Collapse
Affiliation(s)
- Laila M Poisson
- From the Center for Bioinformatics and Departments of Public Health Sciences and
| | | | | | - Indrani Datta
- From the Center for Bioinformatics and Departments of Public Health Sciences and
| | | | - Krzysztof Labuzek
- the Department of Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland
| | - Md Nasrul Hoda
- the Department of Neurology, Georgia Health Sciences University, Augusta, Georgia 30912, the Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, Georgia 30912
| | | | - Ashok Kumar
- the Department of Anatomy and Cell Biology, School of Medicine, Wayne State University, Detroit, Michigan 48202
| | | | | | | | - Moses Rodriguez
- the Departments of Neurology and Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota 55906
| | - Ramandeep Rattan
- Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Health System, Detroit, Michigan 48202
| | - Ashutosh K Mangalam
- the Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242
| | | |
Collapse
|
44
|
Kast R, Auner G, Yurgelevic S, Broadbent B, Raghunathan A, Poisson LM, Mikkelsen T, Rosenblum ML, Kalkanis SN. Identification of regions of normal grey matter and white matter from pathologic glioblastoma and necrosis in frozen sections using Raman imaging. J Neurooncol 2015; 125:287-95. [PMID: 26359131 DOI: 10.1007/s11060-015-1929-4] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Accepted: 09/05/2015] [Indexed: 11/29/2022]
Abstract
In neurosurgical applications, a tool capable of distinguishing grey matter, white matter, and areas of tumor and/or necrosis in near-real time could greatly aid in tumor resection decision making. Raman spectroscopy is a non-destructive spectroscopic technique which provides molecular information about the tissue under examination based on the vibrational properties of the constituent molecules. With careful measurement and data processing, a spatial step and repeat acquisition of Raman spectra can be used to create Raman images. Forty frozen brain tissue sections were imaged in their entirety using a 300-µm-square measurement grid, and two or more regions of interest within each tissue were also imaged using a 25 µm-square step size. Molecular correlates for histologic features of interest were identified within the Raman spectra, and novel imaging algorithms were developed to compare molecular features across multiple tissues. In previous work, the relative concentration of individual biomolecules was imaged. Here, the relative concentrations of 1004, 1300:1344, and 1660 cm(-1), which correspond primarily to protein and lipid content, were simultaneously imaged across all tissues. This provided simple interpretation of boundaries between grey matter, white matter, and diseased tissue, and corresponded with findings from adjacent hematoxylin and eosin-stained sections. This novel, yet simple, multi-channel imaging technique allows clinically-relevant resolution with straightforward molecular interpretation of Raman images not possible by imaging any single peak. This method can be applied to either surgical or laboratory tools for rapid, non-destructive imaging of grey and white matter.
Collapse
Affiliation(s)
- Rachel Kast
- Department of Surgery, Wayne State University, Detroit, MI, 48202, USA.,Department of Biomedical Engineering, Wayne State University, Detroit, MI, 48202, USA.,Smart Sensors and Integrated Microsystems, Wayne State University, Detroit, MI, 48202, USA
| | - Gregory Auner
- Department of Surgery, Wayne State University, Detroit, MI, 48202, USA.,Department of Biomedical Engineering, Wayne State University, Detroit, MI, 48202, USA.,Smart Sensors and Integrated Microsystems, Wayne State University, Detroit, MI, 48202, USA
| | - Sally Yurgelevic
- Department of Surgery, Wayne State University, Detroit, MI, 48202, USA.,Department of Biomedical Engineering, Wayne State University, Detroit, MI, 48202, USA.,Smart Sensors and Integrated Microsystems, Wayne State University, Detroit, MI, 48202, USA
| | - Brandy Broadbent
- Department of Biomedical Engineering, Wayne State University, Detroit, MI, 48202, USA.,Smart Sensors and Integrated Microsystems, Wayne State University, Detroit, MI, 48202, USA
| | - Aditya Raghunathan
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Department of Pathology and Laboratory Medicine, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Josephine Ford Cancer Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Mayo Clinic, Rochester, MN, 55905, USA
| | - Laila M Poisson
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Department of Public Health Sciences, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Josephine Ford Cancer Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA
| | - Tom Mikkelsen
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Josephine Ford Cancer Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA
| | - Mark L Rosenblum
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.,Josephine Ford Cancer Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA
| | - Steven N Kalkanis
- Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA. .,Josephine Ford Cancer Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
| |
Collapse
|
45
|
Thomas SL, Schultz CR, Mouzon E, Golembieski WA, Lemke N, Poisson LM, Gutierrez JA, Cottingham S, Rempel SA. Abstract 2363: Loss of Sparc in p53-null astrocytes alters collagen deposition and promotes macrophage activation and tumor phagocytosis. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-2363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Both the induction of SPARC expression and the loss of the p53 tumor suppressor gene are changes that occur early in glioma development. Therefore, the upregulation of SPARC may cooperate with the loss of p53 to enhance cell survival and inhibit apoptosis during glioma formation. This study determined whether the loss of Sparc in astrocytes that are null for p53 (p53-null/Sparc-null) would result in reduced cell survival and tumor formation and increased tumor immunogenicity in an in vivo xenograft brain tumor model. In vitro, the loss of Sparc in p53-null astrocytes resulted in an increase in cell proliferation (15-33%, p<0.01); however, there was an inhibition of growth in soft agar. Intracranial xenografts of p53-null/Sparc-wt and p53-null/Sparc-null astrocytes were assessed for tumor size, proliferation rate, and SPARC expression. At 7 days post-implantation, Sparc-null astrocytes produced significantly smaller tumors (Wilcoxon rank-sum test p = 0.0091, median = 0.709mm2 for Sparc-wt and 0.240mm2 for Sparc-null) with a significantly lower MIB-1 proliferation index (Wilcoxon rank-sum test p = 0.0345, median = 8.6% for Sparc-wt and 0.4% for Sparc-null). By CD68 and periodic acid Schiff +/- diastase staining of xenograft tumors, it was found that Sparc-null tumors had a massive infiltration of microglia/macrophages with a phagocytic appearance compared to the activated, but non-phagocytic, microglia/macrophages present within the Sparc-wt tumors. The loss of Sparc in astrocytes and the resulting increase in microglia/macrophage activation lead to an alteration in the tumor microenvironment with increased collagen deposition and altered collagen structure at both 7 and 50 days post-implantation as assessed by picrosirius red and polarized light microscopy. Sparc-null tumors had increased collagen deposition with a long fiber structure compared to the small bundles of collagen present in Sparc-wt tumors. Our results indicate that the loss of p53 by deletion/mutation in the early stages of glioma formation may cooperate with the induction of SPARC to potentiate cancer cell survival and escape from immune surveillance.
Citation Format: Stacey L. Thomas, Chad R. Schultz, Ezekiell Mouzon, William A. Golembieski, Nancy Lemke, Laila M. Poisson, Jorge A. Gutierrez, Sandra Cottingham, Sandra A. Rempel. Loss of Sparc in p53-null astrocytes alters collagen deposition and promotes macrophage activation and tumor phagocytosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2363. doi:10.1158/1538-7445.AM2015-2363
Collapse
|
46
|
Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, Cooper LAD, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DPC, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015; 372:2481-98. [PMID: 26061751 PMCID: PMC4530011 DOI: 10.1056/nejmoa1402121] [Citation(s) in RCA: 2118] [Impact Index Per Article: 235.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Collapse
|
47
|
Thomas SL, Schultz CR, Mouzon E, Golembieski WA, El Naili R, Radakrishnan A, Lemke N, Poisson LM, Gutiérrez JA, Cottingham S, Rempel SA. Loss of Sparc in p53-null Astrocytes Promotes Macrophage Activation and Phagocytosis Resulting in Decreased Tumor Size and Tumor Cell Survival. Brain Pathol 2015; 25:391-400. [PMID: 24862407 PMCID: PMC4520390 DOI: 10.1111/bpa.12161] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Accepted: 05/19/2014] [Indexed: 12/26/2022] Open
Abstract
Both the induction of SPARC expression and the loss of the p53 tumor suppressor gene are changes that occur early in glioma development. Both SPARC and p53 regulate glioma cell survival by inverse effects on apoptotic signaling. Therefore, during glioma formation, the upregulation of SPARC may cooperate with the loss of p53 to enhance cell survival. This study determined whether the loss of Sparc in astrocytes that are null for p53 would result in reduced cell survival and tumor formation and increased tumor immunogenicity in an in vivo xenograft brain tumor model. In vitro, the loss of Sparc in p53‐null astrocytes resulted in an increase in cell proliferation, but a loss of tumorigenicity. At 7 days after intracranial implantation, Sparc‐null tumors had decreased tumor cell survival, proliferation and reduced tumor size. The loss of Sparc promoted microglia/macrophage activation and phagocytosis of tumor cells. Our results indicate that the loss of p53 by deletion/mutation in the early stages of glioma formation may cooperate with the induction of SPARC to potentiate cancer cell survival and escape from immune surveillance.
Collapse
Affiliation(s)
- Stacey L Thomas
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI.,Department of Clinical Neurosciences, Laboratory of Molecular Neuro-Oncology, Division of Neurosurgery, Spectrum Health System, Grand Rapids, MI
| | - Chad R Schultz
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI.,Department of Clinical Neurosciences, Laboratory of Molecular Neuro-Oncology, Division of Neurosurgery, Spectrum Health System, Grand Rapids, MI
| | - Ezekiell Mouzon
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI
| | - William A Golembieski
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI.,Department of Clinical Neurosciences, Laboratory of Molecular Neuro-Oncology, Division of Neurosurgery, Spectrum Health System, Grand Rapids, MI
| | - Reima El Naili
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI
| | - Archanna Radakrishnan
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI
| | - Nancy Lemke
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI
| | - Laila M Poisson
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI
| | | | - Sandra Cottingham
- Department of Neuropathology and Clinical Neurosciences, Spectrum Health System, Grand Rapids, MI
| | - Sandra A Rempel
- Department of Neurosurgery, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology and Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI.,Department of Clinical Neurosciences, Laboratory of Molecular Neuro-Oncology, Division of Neurosurgery, Spectrum Health System, Grand Rapids, MI
| |
Collapse
|
48
|
Poisson LM, Munkarah A, Madi H, Datta I, Hensley-Alford S, Tebbe C, Buekers T, Giri S, Rattan R. A metabolomic approach to identifying platinum resistance in ovarian cancer. J Ovarian Res 2015; 8:13. [PMID: 25880539 PMCID: PMC4396147 DOI: 10.1186/s13048-015-0140-8] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 03/09/2015] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Acquisition of metabolic alterations has been shown to be essential for the unremitting growth of cancer, yet the relation of such alterations to chemosensitivity has not been investigated. In the present study our aim was to identify the metabolic alterations that are specifically associated with platinum resistance in ovarian cancer. A global metabolic analysis of the A2780 platinum-sensitive and its platinum-resistant derivative C200 ovarian cancer cell line was performed utilizing ultra-high performance liquid chromatography/mass spectroscopy and gas chromatography/mass spectroscopy. Per-metabolite comparisons were made between cell lines and an interpretive analysis was carried out using the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic library and the Ingenuity exogenous molecule library. RESULTS We observed 288 identified metabolites, of which 179 were found to be significantly different (t-test p < 0.05) between A2780 and C200 cells. Of these, 70 had increased and 109 had decreased levels in platinum resistant C200 cells. The top altered KEGG pathways based on number or impact of alterations involved the cysteine and methionine metabolism. An Ingenuity Pathway Analysis also revealed that the methionine degradation super-pathway and cysteine biosynthesis are the top two canonical pathways affected. The highest scoring network of altered metabolites was related to carbohydrate metabolism, energy production, and small molecule biochemistry. Compilation of KEGG analysis and the common network molecules revealed methionine and associated pathways of glutathione synthesis and polyamine biosynthesis to be most significantly altered. CONCLUSION Our findings disclose that the chemoresistant C200 ovarian cancer cells have distinct metabolic alterations that may contribute to its platinum resistance. This distinct metabolic profile of platinum resistance is a first step towards biomarker development for the detection of chemoresistant disease and metabolism-based drug targets specific for chemoresistant tumors.
Collapse
Affiliation(s)
- Laila M Poisson
- Center for Bioinformatics, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Josephine Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Adnan Munkarah
- Josephine Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Hala Madi
- Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Indrani Datta
- Center for Bioinformatics, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Sharon Hensley-Alford
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Josephine Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Calvin Tebbe
- Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Thomas Buekers
- Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Hospital, Detroit, MI, 48202, USA.
| | - Shailendra Giri
- Josephine Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Department of Neurology, Henry Ford Health System, Detroit, MI, 48202, USA.
| | - Ramandeep Rattan
- Josephine Ford Cancer Institute, Henry Ford Hospital, Detroit, MI, 48202, USA. .,Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Hospital, Detroit, MI, 48202, USA.
| |
Collapse
|
49
|
Berezovsky AD, Poisson LM, Hong X, Mikkelsen T, deCarvalho AC. Abstract 3385: Sox2 is necessary for glioblastoma cell plasticity. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Objective: The HMG-box transcription factor Sox2 is essential for the maintenance of stem cells from early development to adult tissues. Sox2 activates and represses the expression of different gene sets in various tissues during development through HMG-box domain-mediated DNA binding. Sox2 can reprogram differentiated cells into pluripotent cells in concert with other factors, and is overexpressed in various cancers, including glioblastoma (GBM). Employing a GBM patient-derived cancer stem cell (CSC) and isogenic serum differentiated cell (SDC) model we show that Sox2 regulates distinct gene sets in glioblastoma stem and differentiated cells. Experimental Approaches: Differentially expressed genes (DEGs) between Sox2-positive and Sox2-negative cells in SDCs and isogenic CSCs were compiled from genome-wide transcriptome data (Illumina HT12v4.0). Metacore (Thomson Reuters) and IPA (Ingenuity Systems) software applications were used to further analyze the datasets. Gene Expression data obtained from the TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/, July 2, 2012) for 517 GBM cases was used to study genes correlated with Sox2 expression. Results: Sox2 knockdown in GBM SDCs abolished the dedifferentiation and acquisition of CSC phenotype in vitro. Sox2 knockdown affected the expression of 736 genes in SDCs, 453 downregulated and 283 upregulated, and 799 genes in CSCs, 341 downregulated and 458 upregulated. The expression of genes associated with stem cells and malignancy were commonly downregulated in Sox2-deficient CSCs and SDCs. Upon Sox2 knockdown, proneural (PN) and classical (CL) signature genes are downregulated in SDC and modestly in CSC, while mesenchymal (MES) signature genes are upregulated in both groups. Genes previously shown to be associated with pluripontency and CSCs were specifically affected in the CSC state, while ESC self-renewal genes and cytokine signaling were downregulated and the Wnt pathway was activated in differentiated Sox2-deficient cells. Overlap with Sox2 binding to cis-regulatory sequences was observed for 25.1% and 15.1% of DEGs in SDC and CSC, respectively. Significantly, 28.6% of genes positively correlating with Sox2 expression in the TCGA dataset overlapped with the DEGs in HF2303: 3 genes in both CSC and SDC states, 1 in CSCs, and the remaining 12 in the SDC state suggesting that genes correlated with Sox2 expression in the tumors are better represented in SDCs than in CSCs. Conclusions: Our results indicate that Sox2 regulates the expression of key genes and pathways involved in GBM malignancy, in both cancer stem-like and differentiated cells, and maintains plasticity leading to bidirectional conversion between the two states. These findings have significant clinical implications.
Citation Format: Artem D. Berezovsky, Laila M. Poisson, Xin Hong, Tom Mikkelsen, Ana C. deCarvalho. Sox2 is necessary for glioblastoma cell plasticity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3385. doi:10.1158/1538-7445.AM2014-3385
Collapse
Affiliation(s)
| | | | - Xin Hong
- Henry Ford Health System, Detroit, MI
| | | | | |
Collapse
|
50
|
deCarvalho AC, Arnold K, Mueller C, Petricoin EF, Poisson LM, Mikkelsen T. Abstract 3795: Cabozantinib affects multiple signaling pathways in glioblastoma and is effective in a subset of xenograft tumors. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-3795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor characterized by poor prognosis and high recurrence rate. Several new targeted agents are being considered for the adjuvant treatment of GBMs. Cabozantinib, a multi-kinase currently in clinical trials for several malignancies, including glioblastoma, targets c-Met and VEGFR2 receptors, as well as Ret, Kit, Flt-1/3/4, Tie2, and AXL. Our goal is to first evaluate sensitivity and molecular response of patient-derived GBM cancer stem cells (CSCs) to XL184 in vitro. Anti-tumor efficacy of cabozantinib as a single agent and in combination with the DNA-alkylating agent temozolomide (TMZ) in orthotopic xenografts was then evaluated.
Methods: Neurospheres enriched in CSCs were cultured from resected GBM tumors. Sensitivity to cabozantinib was determined in vitro. Cells were treated (IC40) in triplicate, and cell lysates were analyzed by reverse phase protein microarrays. GBM CSCs were implanted intracranially into nude mice. Cabozantinib was administered by oral gavage at a dose of 60mg/kg for 4 weeks (5 days/week) as a single agent or in combination with 40mg/kg TMZ. Tumor growth and response to treatment were monitored by non-invasive in vivo biolumiescent imaging (BLI) using the Xenogen IVIS System (Caliper Life Sciences), and overall survival.
Results: Sensitivity to cabozantinib treatment varied for the different GBM CSCs. From 70 proteins and phosphoproteins measured, 29 distributed among several signaling pathways were significantly altered after treatment in both resistant and sensitive GBM CSCs. Cabozantinib single agent treatment reduced GBM tumor growth and increased mouse survival in two xenograft lines. Cabozantinib monotherapy reduced tumor size, as measured by BLI, but had no significant effect on overall survival for another xenograft line, however, the combination treatment resulted in sensitization of these xenografts to TMZ treatment.
Conclusion: The use of multi-kinase inhibitors is a promising strategy for GBMs, and given the range of responses, identifying predictive biomarkers, though challenging, will be invaluable for patient stratification.
Citation Format: Ana C. deCarvalho, Kimberly Arnold, Claudius Mueller, Emanuel F. Petricoin, Laila M. Poisson, Tom Mikkelsen. Cabozantinib affects multiple signaling pathways in glioblastoma and is effective in a subset of xenograft tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3795. doi:10.1158/1538-7445.AM2014-3795
Collapse
|